{"gene":"VWF","run_date":"2026-04-28T23:00:23","timeline":{"discoveries":[{"year":1985,"finding":"VWF cDNA clones spanning 8.2 kb of mRNA were isolated from human endothelial cells; the VWF gene was localized to chromosome 12p12-12pter, and VWF accounts for ~0.3% of endothelial cell mRNA.","method":"cDNA library screening, chromosomal localization by in situ hybridization","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — original cDNA cloning with chromosomal mapping, foundational paper with 415 citations","pmids":["3874428"],"is_preprint":false},{"year":1985,"finding":"VWF cDNA encodes a precursor protein with a signal peptide, propeptide, and mature subunit; the carboxyl-terminal portion contains internal gene duplications and the cell-attachment tetrapeptide Arg-Gly-Asp-Ser.","method":"cDNA cloning and sequencing, amino acid sequence comparison","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — direct cDNA sequencing with protein sequence validation, foundational paper","pmids":["2864688"],"is_preprint":false},{"year":1986,"finding":"Full-length VWF cDNA encodes a single-chain precursor of 2813 amino acids with a signal peptide (22 aa), prosequence (741 aa, domains D1-D2), and mature VWF (2050 aa); the domain structure is D1-D2-D'-D3-A1-A2-A3-D4-B1-B2-C1-C2; in vitro expression confirmed synthesis of the unglycosylated precursor.","method":"Full-length cDNA assembly and in vitro expression in COS-1 cells","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — complete cDNA sequencing plus in vitro expression, 241 citations","pmids":["3019665"],"is_preprint":false},{"year":1986,"finding":"The amino acid sequence of mature VWF (2050 residues) was determined; it contains 12 Asn-linked and 10 Thr/Ser-linked oligosaccharide chains, and shows homology to complement factor B.","method":"Direct protein sequencing (Edman degradation) combined with cDNA-derived sequence","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — complete protein sequencing with carbohydrate site mapping, 451 citations","pmids":["3524673"],"is_preprint":false},{"year":1986,"finding":"VWF is localized to Weibel-Palade bodies in human endothelial cells; constitutively secreted VWF is predominantly dimeric with pro-VWF subunits, whereas inducible secretion (by thrombin or calcium ionophore) releases only very large multimers of mature subunits that are more active in platelet binding.","method":"Immunofluorescence, immunoperoxidase/electron microscopy, stimulated secretion assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 — direct organelle localization plus functional characterization of two secretory pathways, 430 and 657 citations across two key papers","pmids":["3087627","6754744"],"is_preprint":false},{"year":1987,"finding":"The VWF propeptide (domains D1-D2) is required for multimerization beyond the dimer stage: COS-1 cells expressing a propeptide-deleted VWF cDNA produce only dimers, demonstrating that dimerization is propeptide-independent but multimerization requires the propeptide.","method":"Heterologous expression of full-length and propeptide-deleted VWF cDNA in COS-1 cells","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — direct mutagenesis and expression showing propeptide requirement for multimerization, 115 citations","pmids":["3500851"],"is_preprint":false},{"year":1987,"finding":"N-linked glycosylation of VWF is required for efficient secretion; VWF transiently associates with BiP (heavy chain-binding protein) during biosynthesis in CHO cells, and this association dissipates as the protein is glycosylated and secreted.","method":"Tunicamycin treatment, co-immunoprecipitation of BiP with VWF in CHO cells","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — co-IP and chemical inhibition showing BiP–VWF association dependent on glycosylation state, 335 citations","pmids":["3121636"],"is_preprint":false},{"year":1989,"finding":"The VWF gene spans ~178 kb and contains 52 exons (40 bp to 1379 bp); the signal peptide and propeptide are encoded by 17 exons in ~80 kb, and the mature subunit by 35 exons in ~100 kb; domain-encoding exon structure supports origin by gene segment duplication.","method":"Cosmid library screening, restriction mapping, complete sequencing of exon-intron boundaries","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — complete gene structure determination, 448 citations","pmids":["2584182"],"is_preprint":false},{"year":1990,"finding":"PACE (Paired basic Amino acid Cleaving Enzyme, later furin) cleaves the VWF propeptide at the paired basic amino acid site (Arg-Ser cleavage site); co-expression of PACE with VWF in COS-1 cells enhanced propeptide processing.","method":"cDNA cloning of PACE, co-expression with VWF precursor in COS-1 cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — reconstitution of propeptide cleavage by identified enzyme in cells, 315 citations","pmids":["2251280"],"is_preprint":false},{"year":1996,"finding":"GPIbα binding to immobilized VWF supports fast-on/fast-off platelet tethering and translocation at shear rates >6000 s⁻¹; this mechanism allows subsequent αIIbβ3 activation and firm arrest on VWF, coupling two distinct adhesion mechanisms.","method":"Flow chamber assays with defined shear rates, blocking antibodies and glycoprotein-deficient platelets","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — rigorous flow-based functional assay demonstrating two-step platelet adhesion mechanism, 963 citations","pmids":["8565074"],"is_preprint":false},{"year":1996,"finding":"VWF undergoes a shear-stress-induced conformational transition from a globular (~149×77 nm) to an extended chain conformation at a critical shear stress of ~35 dyn/cm², with exposure of intramolecular globular domains; this structural change is directional, aligned with shear.","method":"Atomic force microscopy of VWF on hydrophobic surfaces under defined shear stress","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — direct structural imaging under controlled shear, 460 citations","pmids":["8874190"],"is_preprint":false},{"year":1998,"finding":"VWF mediates platelet adhesion through binding to platelet GPIb and to subendothelial connective tissue components; VWF also serves as carrier for factor VIII, protecting it from proteolytic degradation; VWF multimer size is regulated by ADAMTS13-like proteolysis and allosteric mechanisms involving hydrodynamic shear.","method":"Comprehensive biochemical review synthesizing purification, binding, and mutagenesis data","journal":"Annual review of biochemistry","confidence":"High","confidence_rationale":"Tier 1 — synthesis of multiple reconstitution and structural studies, 1108 citations","pmids":["9759493"],"is_preprint":false},{"year":1999,"finding":"Non-activated FVIII circulates in a complex with VWF; upon thrombin- or FXa-mediated activation, FVIII dissociates from VWF with concomitant conformational change in the C2 domain, dramatically increasing FVIII affinity for phospholipid surfaces and enabling factor Xase complex assembly.","method":"In vitro proteolysis, binding assays with phospholipid vesicles, domain mutagenesis","journal":"Trends in cardiovascular medicine","confidence":"High","confidence_rationale":"Tier 1–2 — mechanistic dissection of FVIII–VWF dissociation and Xase assembly using biochemical reconstitution","pmids":["10881749"],"is_preprint":false},{"year":2001,"finding":"The A3 domain of VWF mediates collagen binding; a Ser968Thr substitution in the A3 domain abolishes collagen binding while preserving VWF multimeric structure and GPIb binding, identifying Ser968 as critical for collagen interaction.","method":"Site-directed mutagenesis of full-length VWF cDNA, transient expression in COS-7 cells, collagen binding assays","journal":"Thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis with functional validation in recombinant system, confirmed in patient plasma","pmids":["11583318"],"is_preprint":false},{"year":2002,"finding":"The D1 domain of the VWF propeptide is critical for N-terminal multimerization; a Tyr87Ser mutation in D1 results in predominantly dimeric VWF with loss of collagen binding, factor VIII binding, and ristocetin-induced platelet binding, but normal granular storage, indicating the propeptide acts as an intramolecular chaperone for multimerization.","method":"Patient mutation identification, recombinant VWF expression, multimer analysis, functional binding assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — patient mutation, recombinant expression and multiple orthogonal functional assays","pmids":["12176890"],"is_preprint":false},{"year":2002,"finding":"Crystal structures of GPIbα amino-terminal domain and its complex with VWF A1 domain revealed that GPIbα wraps around one side of A1 at two contact areas bridged by solvated charge interactions; gain-of-function mutations in bleeding disorders map to these interfaces.","method":"X-ray crystallography of GPIbα alone and GPIbα–VWF A1 complex","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with direct functional mapping, 467 citations","pmids":["12183630"],"is_preprint":false},{"year":2003,"finding":"The collagen-binding site of the VWF A3 domain is located on its hydrophobic 'front' surface, as determined by transferred cross-saturation NMR; this binding surface is distinct from the 'top' surface used by the integrin α2-I domain despite shared fold and function.","method":"Transferred cross-saturation NMR on A3 domain–fibrillar collagen complex","journal":"Nature structural biology","confidence":"High","confidence_rationale":"Tier 1 — NMR method providing atomic-resolution contact map, validated against structural homolog","pmids":["12447349"],"is_preprint":false},{"year":2003,"finding":"VWF–FVIII complex bound with VWF is cleared predominantly by Kupffer cells/macrophages in the liver; free FVIII unbound from VWF is cleared by hepatocytes via a VWF-independent pathway.","method":"Pharmacokinetic studies, immunohistochemistry in VWF-null mice, FcRn chimeric mice","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo biodistribution with immunohistochemistry in multiple mouse models","pmids":["25905473"],"is_preprint":false},{"year":2004,"finding":"VWF is essential for Weibel-Palade body (WPB) biogenesis in endothelial cells; re-expression of wild-type VWF in VWF-null canine aortic endothelial cells restored WPBs that recruited endogenous P-selectin; VWF multimerization is not required for WPB creation, but the propeptide alone cannot independently induce granule formation.","method":"Canine VWD endothelial cell model, lentiviral re-expression, confocal immunofluorescence","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — VWF-null endothelial cell reconstitution with multiple VWF mutants and direct organelle imaging","pmids":["15331450"],"is_preprint":false},{"year":2005,"finding":"14-3-3ζ binding to the cytoplasmic tail of GPIbα (and GPIbβ) regulates the VWF-binding function of the GPIb-IX complex; a membrane-permeable inhibitor of 14-3-3ζ–GPIbα interaction potently inhibited VWF binding to platelets and VWF-mediated platelet adhesion under flow.","method":"Membrane-permeable inhibitor peptide, mutagenesis of 14-3-3ζ binding site in GPIbβ, flow adhesion assays, ristocetin agglutination","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — pharmacological and genetic disruption of 14-3-3ζ interaction with defined functional readout","pmids":["15941906"],"is_preprint":false},{"year":2005,"finding":"GPIb-IX-mediated botrocetin/VWF agglutination triggers TxA2 production via a signaling cascade initiated by Lyn, enhanced by Src, and propagated through Syk, SLP-76, PI3K, PLCγ2, and PKC; LAT and FcRγ-chain are not required for TxA2 production but are required for granule secretion.","method":"Genetic knockout mouse platelets (Lyn, Src, Syk, SLP-76, PLCγ2, LAT, FcRγ), pharmacological inhibitors, wortmannin","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — systematic epistasis analysis using multiple knockout mouse lines","pmids":["15985541"],"is_preprint":false},{"year":2005,"finding":"Platelets contain functionally active ADAMTS13 on their surface; platelet ADAMTS13 activity increases upon thrombin receptor-activating peptide (but not ADP) stimulation, and can cleave endothelial-derived ultra-large VWF multimers under static and flow conditions.","method":"Platelet lysate VWF cleavage assays, ADAMTS13 antibody inhibition, flow cytometry for surface ADAMTS13","journal":"Journal of thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 2 — multiple antibodies against different ADAMTS13 domains, functional cleavage assays with inhibition controls","pmids":["16176307"],"is_preprint":false},{"year":2006,"finding":"Bruton tyrosine kinase (Btk) is required for GPIb-mediated VWF-induced platelet signaling leading to TxA2 production; Btk acts downstream of Lyn, Syk, SLP-76, and PI3K, and upstream of ERK1/2, PLCγ2, and PKC; Btk is also essential for GPIb-dependent arterial thrombus formation in vivo.","method":"Btk-knockout and Tec-knockout mouse platelets, ferric chloride carotid artery injury model, kinase inhibitors","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic KO epistasis placing Btk in signaling pathway, confirmed in vivo thrombosis model","pmids":["16788103"],"is_preprint":false},{"year":2006,"finding":"Chloride ions bind specifically to the VWF A1 domain (not A2), stabilizing its folded conformation and allosterically inhibiting ADAMTS13-mediated cleavage of the Tyr1605-Met1606 bond in the A2 domain; the R1306W type 2B VWD mutation reduces chloride affinity for the A1 domain.","method":"Urea-induced unfolding spectroscopy, isothermal titration calorimetry, ADAMTS13 cleavage assays with isolated VWF domains","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — thermodynamic and enzymatic characterization with domain-specific mutants identifying allosteric chloride binding site","pmids":["16899464"],"is_preprint":false},{"year":2007,"finding":"N-linked glycans at VWF residue N1574 (but not N1515) sterically inhibit ADAMTS13-mediated cleavage; removal of N-linked glycans (PNGaseF) increases VWF affinity for ADAMTS13 ~4-fold and allows cleavage without urea denaturation; ABO(H) blood group sugars occupy N1515 and N1574.","method":"PNGaseF digestion, site-directed mutagenesis of N-glycosylation sites in recombinant VWF and isolated A2 domain, ADAMTS13 binding/cleavage assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis of specific glycosylation sites with reconstituted cleavage assays","pmids":["17975018"],"is_preprint":false},{"year":2008,"finding":"Src family kinase Lyn mediates VWF/GPIb-IX-induced stable platelet adhesion under shear stress via elevation of cGMP independently of TxA2 synthesis; Fyn mediates the TxA2-dependent second wave of aggregation but not stable adhesion; low-concentration 8-bromo-cGMP corrects Lyn-KO adhesion defect.","method":"Lyn-KO and Fyn-KO mouse platelets, flow adhesion on VWF, cGMP measurements, 8-bromo-cGMP rescue","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with epistasis, pharmacological rescue with cGMP analog defining pathway","pmids":["18550847"],"is_preprint":false},{"year":2009,"finding":"VWF A2 domain is mechanically unfolded by elongational forces in the physiological range (force proportional to multimer length squared, highest at the center of the multimer); only the unfolded A2 domain is cleaved by ADAMTS13, providing a homeostatic mechanism for size regulation by force-induced cleavage.","method":"Single-molecule force spectroscopy (optical tweezers), shear flow experiments, ADAMTS13 cleavage of unfolded A2","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — single-molecule reconstitution demonstrating force-dependent A2 unfolding and ADAMTS13 cleavage, 408 citations","pmids":["19498171"],"is_preprint":false},{"year":2009,"finding":"Rab27a and its effector MyRIP anchor mature Weibel-Palade bodies to peripheral actin; depletion of Rab27a or MyRIP increases both basal and stimulated VWF secretion, but the released VWF is less multimerized and VWF strings under flow are shorter, indicating this complex controls peripheral WPB distribution and prevents release of incompletely processed VWF.","method":"siRNA depletion in primary endothelial cells, live imaging, WPB localization, VWF multimer analysis, flow-induced string assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — siRNA knockdown with multiple orthogonal functional readouts in primary cells","pmids":["19270261"],"is_preprint":false},{"year":2010,"finding":"VWF A1 domain unfolding from native to intermediate state (reduction of disulfide bond) increases GPIbα binding affinity ~20-fold; A1:GPIbα binding is thermodynamically coupled to A1 unfolding, and catch-to-slip bond transition under shear force is a manifestation of this coupling.","method":"Thermodynamic unfolding analysis, circular dichroism, GPIbα binding affinity measurements under reducing conditions","journal":"Biophysical journal","confidence":"High","confidence_rationale":"Tier 1 — thermodynamic reconstitution with quantitative allosteric model","pmids":["20713003"],"is_preprint":false},{"year":2010,"finding":"VWF deficiency in endothelial cells (siRNA or VWD patient-derived progenitor cells) causes increased VEGFR-2-dependent proliferation and migration, decreased integrin αvβ3, and increased Ang-2 release, resulting in enhanced angiogenesis; VWF-deficient mice show increased vascularization in vivo.","method":"siRNA knockdown in HUVECs, EPC-derived cells from VWD patients, in vitro tube formation, mouse vascularization models","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — siRNA and patient-derived cells with multiple orthogonal readouts in vitro and in vivo, 389 citations","pmids":["21048155"],"is_preprint":false},{"year":2010,"finding":"Thrombospondin-1 (TSP1) competitively inhibits ADAMTS13 binding to VWF A2 and A3 domains, blocking ADAMTS13 cleavage by up to 70%; TSP1 also binds A1 domain, whereas ADAMTS13 interacts with all three A domains.","method":"ELISA binding assays with recombinant VWF A domains, western blot, residual collagen-binding assay for ADAMTS13 activity","journal":"Thrombosis research","confidence":"Medium","confidence_rationale":"Tier 3 — binding assays with functional inhibition assay, single lab","pmids":["20705333"],"is_preprint":false},{"year":2012,"finding":"VWF propeptide (VWFpp) binds specifically to the D'D3 domain of mature VWF with high affinity under intracellular (pH 6.2, 10 mM Ca²⁺) conditions (KD = 0.2 nM) and weaker affinity under physiological plasma conditions (KD = 25–50 nM); this persistent binding in circulation attenuates VWF platelet adhesion by reducing GPIbα engagement.","method":"Surface plasmon resonance, novel anti-D'D3 mAbs, shear-induced platelet aggregation assays, flow chamber adhesion assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — quantitative binding kinetics by SPR plus functional platelet assays with blocking antibodies","pmids":["22452980"],"is_preprint":false},{"year":2014,"finding":"The kinetic interplay between two distinct GPIbα–VWF A1 contact surfaces regulates hemostasis and thrombosis: a mutation enhancing the minor site (I1309V) prolongs bond lifetime and produces type 2B VWD-like thrombocytopenia, while disrupting the major site (R1326H) shortens bond lifetime and produces hemostatic defects comparable to VWF deficiency; combining both mutations normalizes kinetics and function.","method":"VWF-A1 knock-in mice (I1309V, R1326H, double mutant), flow chamber assays, intravital microscopy, tail bleeding times","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — multiple knock-in mouse models with in vitro and in vivo functional readouts","pmids":["25293780"],"is_preprint":false},{"year":2016,"finding":"A silent mutation (c.7464C>T) in VWF exon 44 causes intron 44 retention by inducing a stable hairpin structure 85 bp upstream of the 5' splice site that sequesters residues required for U1 snRNA interaction, resulting in a truncated VWF protein that accumulates in the endoplasmic reticulum.","method":"Patient transcript analysis, in vivo and ex vivo RT-PCR, confocal immunofluorescence of blood outgrowth endothelial cells, in silico pre-mRNA secondary/tertiary structure prediction","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — patient mutation, transcript analysis, protein mislocalization confirmed by immunofluorescence, structural mechanism validated in silico","pmids":["27543438"],"is_preprint":false},{"year":2016,"finding":"HMGB1 upregulates VWF expression in vivo through a TLR2–MYD88–SP1 signaling pathway; TLR2 silencing abolishes MYD88 and VWF expression and SP1 phosphorylation, and glycyrrhizic acid or Tlr2 silencing blocks Sp1 binding to the Vwf promoter.","method":"Mouse acute hypoxia model, Tlr2 siRNA knockdown, TLR2-neutralizing antibody, SP1 inhibitor, chromatin immunoprecipitation (ChIP) of Sp1 at Vwf promoter","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo knockdown with ChIP validation of promoter binding, single lab","pmids":["27480067"],"is_preprint":false},{"year":2017,"finding":"GATA3 mediates upregulation of VWF transcription in lung adenocarcinoma-associated endothelial cells; conditioned medium from A549 cells increases GATA3 binding to a GATA binding motif at +220 of the VWF promoter, as confirmed by ChIP.","method":"Co-culture system with conditioned medium, ChIP assay for GATA3 at VWF promoter, siRNA knockdown of GATA3 vs ERG","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP confirming direct transcription factor binding at VWF promoter with functional siRNA validation","pmids":["29299165"],"is_preprint":false},{"year":2018,"finding":"Extracellular vimentin on the endothelial surface binds the VWF A2 domain to tether VWF strings; Vim-KO mouse cerebral arteries produce fewer VWF strings after histamine stimulation, and recombinant A2 protein or anti-vimentin antibodies block VWF string formation; A2 treatment improved cortical reperfusion after stroke in mice.","method":"Histamine stimulation of pressurized cerebral arteries, Vim-KO mice, anti-vimentin antibodies, recombinant A2 domain blockade, laser speckle contrast imaging","journal":"Stroke","confidence":"High","confidence_rationale":"Tier 2 — genetic KO plus pharmacological blocking in multiple complementary in vitro and in vivo systems","pmids":["30355099"],"is_preprint":false},{"year":2019,"finding":"Extracellular PAD4 citrullinates ADAMTS13 on specific arginine residues, inhibiting its enzymatic activity; this leads to persistence of VWF-platelet strings in mesenteric venules and accelerates platelet plug formation after vessel injury; elevated ADAMTS13 citrullination was found in sepsis and elderly patients with comorbidities.","method":"In vivo r-huPAD4 injection intravital microscopy, mass spectrometry for citrullination sites, in vitro ADAMTS13 activity assays, ferric chloride injury model","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 1–2 — MS identification of citrullination sites with in vitro functional assay and in vivo validation","pmids":["31248335"],"is_preprint":false},{"year":2020,"finding":"VWF maturation and release are controlled by two distinct regulators of Weibel-Palade body biogenesis: BLOC-2 (required for endosomal input during VWF maturation and WPB exocytosis) and the exocyst complex (which cooperates in WPB formation but clamps WPB release); WPBs from BLOC-2- or exocyst-depleted cells lack high-molecular-weight VWF forms.","method":"siRNA depletion of BLOC-2 and exocyst subunits, immunoprecipitation identifying BLOC-2–exocyst interaction, VWF multimer analysis of releasates, Endosidin2 pharmacological inhibition","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — reciprocal IP, siRNA knockdown with VWF multimer functional readout, pharmacological confirmation","pmids":["32614949"],"is_preprint":false},{"year":2020,"finding":"Platelets docking to endothelial VWF during inflammation secrete Angiopoietin-1 (Angpt1) that activates Tie-2 via the Cdc42-GEF FGD5 pathway, preventing vascular leaks during neutrophil extravasation; blocking VWF caused leaks during transmigration.","method":"Endothelial Tie-2 gene silencing and knockout, intravital microscopy of cremaster muscle, platelet-derived Angpt1 conditional KO, anti-VWF antibody blocking, fluorescent microsphere leakage assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic KO models with defined molecular pathway and intravital imaging readout","pmids":["32369573"],"is_preprint":false},{"year":2021,"finding":"Hyperadhesive VWF released during traumatic brain injury has its A1 domain constitutively exposed; selective blockade with recombinant VWF A2-domain protein reduced TBI-induced death by >50%, prevented TBI-induced platelet activation, microvesiculation, and hypercoagulable state, and protected endothelium from extracellular vesicle injury.","method":"Mouse lateral fluid percussion TBI model, A2 domain blockade (IP and IV), platelet activation assays, coagulation assays, mortality and neurological scoring","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — conformation-selective blockade in vivo with multiple mechanistic readouts","pmids":["33507292"],"is_preprint":false},{"year":2021,"finding":"Slc44a2/HNA-3a on neutrophils mediates adhesion to VWF at venous shear rates (100 s⁻¹) independently of β2 integrin; HNA-3b expression impairs this adhesion; Slc44a2-KO mice show massively reduced neutrophil recruitment in inflamed mesenteric venules after histamine-induced endothelial degranulation.","method":"Flow chamber adhesion assays with transfected HEK cells and donor-typed neutrophils, Slc44a2-KO mouse intravital microscopy","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — allele-specific functional assays in human cells and genetic KO mouse model","pmids":["33556175"],"is_preprint":false},{"year":2022,"finding":"VWF mediates vascular smooth muscle cell (VSMC) proliferation through its A2 domain binding to LRP4 receptor, which signals via αvβ3 integrin; LRP4 and αvβ3 co-localize by proximity ligation and co-immunoprecipitation; VWF-deficient mice show reduced hyperplasia in carotid ligation and femoral denudation models.","method":"siRNA against αv integrin and LRP4, RGT-peptide blocking, proximity ligation, co-IP, VWF-KO mouse arterial injury models, confocal microscopy","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 — multiple siRNA experiments, co-IP, and in vivo KO with defined pathway","pmids":["33576766"],"is_preprint":false},{"year":2024,"finding":"VWF A1 domain residues K1405–K1408 mediate binding to macrophage LRP1 (clusters II and IV); alanine mutagenesis of this cluster attenuates LRP1 binding and reduces VWF clearance in vivo; the aptamer BT200/rondaptivon pegol prolongs VWF half-life by blocking this interaction and also inhibiting macrophage galactose lectin and SR-AI scavenger receptor binding.","method":"LRP1 binding assays, alanine mutagenesis of K1405-K1408, in vivo clearance studies in mice, BT200 competition assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1–2 — mutagenesis identifying specific residues in VWF-A1 required for LRP1-mediated clearance, validated in vivo","pmids":["38996211"],"is_preprint":false},{"year":2024,"finding":"Endothelial PTP1B deletion promotes VWF exocytosis by increasing SNAP23 phosphorylation (through reduced PTP1B-mediated tyrosine dephosphorylation of SNAP23), leading to enhanced Weibel-Palade body membrane fusion, neutrophil adhesion, and venous thromboinflammation; NF-κB inhibition restored normal SNAP23 phosphorylation and VWF release.","method":"Inducible endothelial PTP1B-KO mice, inferior vena cava ligation, SNAP23 phosphorylation assays, co-IP of PTP1B with SNAP23, anti-VWF antibody blocking, intravital microscopy","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 — genetic KO with identified molecular mechanism (PTP1B–SNAP23 axis) and multiple functional readouts in vivo","pmids":["38563147"],"is_preprint":false}],"current_model":"VWF is a large multimeric glycoprotein synthesized as a pre-pro-polypeptide (D1-D2-D'-D3-A1-A2-A3-D4-B-C domains) in endothelial cells and megakaryocytes; the propeptide (D1-D2) acts as an intramolecular chaperone required for disulfide-linked multimerization, after which furin/PACE cleaves the propeptide; mature ultra-large multimers are stored in Weibel-Palade bodies (whose biogenesis requires VWF itself, BLOC-2, and the exocyst complex, with Rab27a/MyRIP anchoring mature WPBs to peripheral actin) and released upon stimulation; shear stress unfolds the A2 domain to enable force-dependent ADAMTS13 cleavage (regulated by chloride-binding to A1 and N-glycosylation at N1574), controlling multimer size; the exposed A1 domain mediates platelet GPIbα catch-slip bond adhesion (regulated allosterically by 14-3-3ζ and by the VWF propeptide binding to D'D3 in plasma), activating downstream signaling through Lyn–cGMP and Lyn/Syk/Btk–TxA2 pathways; the A3 domain binds fibrillar collagen at its hydrophobic front surface; VWF carries and protects factor VIII from proteolysis (FVIII dissociates upon thrombin-mediated activation), and VWF clearance occurs via macrophage/Kupffer cell LRP1 (through A1-domain K1405-K1408) and galactose lectin receptors; VWF also regulates angiogenesis (via Ang-2 and VEGFR-2), VSMC proliferation (via A2-LRP4-αvβ3 signaling), and endothelial barrier integrity during neutrophil extravasation (via platelet Angpt1-Tie-2 axis), with its exocytosis regulated by SNAP23 phosphorylation downstream of PTP1B."},"narrative":{"teleology":[{"year":1985,"claim":"Isolation and chromosomal mapping of VWF cDNA established its identity as an endothelial-cell-derived gene on chromosome 12p, providing the molecular foundation for dissecting VWF structure and disease mutations.","evidence":"cDNA library screening from endothelial cells with in situ hybridization mapping","pmids":["3874428","2864688"],"confidence":"High","gaps":["Promoter elements and transcriptional regulation not yet defined","Megakaryocyte expression not characterized at this stage"]},{"year":1986,"claim":"Full-length sequencing revealed VWF's complete domain architecture (D1-D2-D'-D3-A1-A2-A3-D4-B-C), glycosylation map, and dual secretory pathways—constitutive (dimeric) vs. regulated (ultra-large multimers from Weibel-Palade bodies)—establishing the framework for understanding how domain structure relates to hemostatic function.","evidence":"Complete cDNA/protein sequencing, in vitro expression in COS-1 cells, immunoelectron microscopy of WPBs, stimulated secretion assays","pmids":["3019665","3524673","3087627","6754744"],"confidence":"High","gaps":["Mechanism of WPB biogenesis unknown","Signals governing regulated exocytosis undefined"]},{"year":1987,"claim":"The propeptide (D1-D2) was shown to be required for multimerization beyond the dimer stage, functioning as an intramolecular chaperone, while N-glycosylation was found necessary for efficient ER exit—defining two critical quality-control steps in VWF biosynthesis.","evidence":"Propeptide-deleted VWF expression in COS-1 cells; tunicamycin treatment and BiP co-immunoprecipitation in CHO cells","pmids":["3500851","3121636"],"confidence":"High","gaps":["Structural basis of propeptide-assisted multimerization unresolved","Disulfide isomerase(s) mediating interchain bonds not identified"]},{"year":1990,"claim":"Identification of furin/PACE as the enzyme cleaving the VWF propeptide resolved the maturation step linking pro-VWF to circulating multimers.","evidence":"Co-expression of PACE cDNA with VWF precursor in COS-1 cells","pmids":["2251280"],"confidence":"High","gaps":["Compartment-specific timing of cleavage relative to multimerization not established","Whether other proprotein convertases contribute in vivo"]},{"year":1996,"claim":"Two breakthrough findings—that GPIbα supports fast-on/fast-off platelet tethering under high shear and that VWF undergoes a shear-induced globular-to-extended conformational transition—explained how VWF functions as a mechanosensitive adhesive molecule.","evidence":"Flow chamber assays with blocking antibodies; atomic force microscopy under controlled shear","pmids":["8565074","8874190"],"confidence":"High","gaps":["Molecular basis of catch bond not yet defined","Which domains unfold first under shear unknown"]},{"year":2002,"claim":"Crystal structure of the GPIbα–VWF A1 complex revealed the atomic interface underlying platelet adhesion, while a patient D1-domain mutation (Tyr87Ser) confirmed the propeptide's chaperone role for multimerization and downstream functions.","evidence":"X-ray crystallography of GPIbα–A1 complex; patient mutation with recombinant VWF expression and binding assays","pmids":["12183630","12176890"],"confidence":"High","gaps":["How flanking domains modulate A1–GPIbα affinity in full-length VWF","Structural mechanism of propeptide-assisted disulfide bonding"]},{"year":2003,"claim":"NMR mapping of the A3 domain–collagen interface to a hydrophobic 'front' surface identified a binding mode distinct from integrin α2-I domains, defining VWF's collagen-recognition mechanism at atomic resolution.","evidence":"Transferred cross-saturation NMR on A3–fibrillar collagen complex","pmids":["12447349"],"confidence":"High","gaps":["Relative contributions of collagen types I vs III in vivo not resolved","Structural basis of A3–A1 cooperativity unknown"]},{"year":2004,"claim":"Reconstitution of WPB biogenesis by re-expression of VWF in VWF-null endothelial cells proved that VWF itself drives WPB formation, recruiting P-selectin and other cargo, establishing VWF as the organizing molecule of its own storage organelle.","evidence":"Lentiviral VWF re-expression in canine VWD endothelial cells, confocal immunofluorescence","pmids":["15331450"],"confidence":"High","gaps":["Minimal VWF domain requirements for WPB nucleation not defined","Cargo sorting signals for other WPB residents unclear"]},{"year":2005,"claim":"Systematic epistasis analysis using knockout mouse platelets placed Lyn, Syk, SLP-76, PI3K, PLCγ2, and Btk in a GPIbα–VWF-triggered signaling cascade leading to TxA₂ production, and identified 14-3-3ζ as an allosteric regulator of GPIb-IX VWF-binding function.","evidence":"Multiple KO mouse platelet systems, pharmacological inhibitors, ristocetin agglutination, flow adhesion","pmids":["15985541","15941906"],"confidence":"High","gaps":["How GPIbα mechanotransduction initiates Lyn activation at the membrane","Role of LAT and FcRγ in granule secretion vs TxA₂ not fully separated"]},{"year":2006,"claim":"Discovery that chloride ions bind to the VWF A1 domain and allosterically inhibit ADAMTS13 cleavage of the A2 domain revealed an ionic regulatory mechanism for multimer size control, with disease mutation R1306W reducing chloride affinity.","evidence":"ITC, urea-unfolding spectroscopy, ADAMTS13 cleavage assays on isolated domains","pmids":["16899464"],"confidence":"High","gaps":["Physiological chloride concentration fluctuations at sites of hemostasis not characterized","Structural basis of allosteric transmission from A1 chloride site to A2 cleavage site"]},{"year":2007,"claim":"Site-directed mutagenesis demonstrated that N-glycosylation at N1574 sterically inhibits ADAMTS13 cleavage of VWF, providing a molecular explanation for ABO blood group influence on VWF multimer size and thrombosis risk.","evidence":"PNGaseF digestion and N-glycosylation-site mutagenesis in recombinant VWF, ADAMTS13 binding/cleavage assays","pmids":["17975018"],"confidence":"High","gaps":["Precise structural model of how the glycan at N1574 shields the cleavage site","Whether O-glycans also regulate cleavage"]},{"year":2009,"claim":"Single-molecule force spectroscopy proved that elongational shear forces unfold the VWF A2 domain in a size-dependent manner (force scales with multimer length squared), with only the unfolded state being an ADAMTS13 substrate—establishing the homeostatic force-cleavage mechanism.","evidence":"Optical tweezers on single VWF molecules, ADAMTS13 cleavage of mechanically unfolded A2","pmids":["19498171"],"confidence":"High","gaps":["In vivo force measurements at the single-multimer level not achieved","Contribution of A2 refolding kinetics to net cleavage rate"]},{"year":2009,"claim":"Rab27a and MyRIP were identified as peripheral actin anchors for WPBs, controlling both distribution and release; their depletion caused premature secretion of less-multimerized VWF, linking WPB positioning to VWF quality.","evidence":"siRNA depletion in primary endothelial cells, live imaging, VWF multimer analysis, flow string assays","pmids":["19270261"],"confidence":"High","gaps":["How Rab27a senses stimulatory signals to release the WPB anchor","Whether MyoVa motor also participates"]},{"year":2010,"claim":"VWF was revealed to regulate endothelial angiogenesis: VWF deficiency causes increased VEGFR-2-dependent proliferation, elevated Ang-2 release, and enhanced vascularization, establishing a non-hemostatic vascular role for VWF.","evidence":"siRNA in HUVECs, VWD patient-derived EPCs, in vitro tube formation, VWF-null mouse vascularization models","pmids":["21048155"],"confidence":"High","gaps":["Mechanism by which intracellular VWF restrains Ang-2 secretion not fully defined","Whether therapeutic VWF replacement reverses angiogenic phenotype in VWD patients"]},{"year":2012,"claim":"Quantitative SPR showed VWF propeptide persists bound to D'D3 in plasma (KD ~25–50 nM), attenuating GPIbα engagement—revealing an unexpected circulating regulatory mechanism for VWF platelet adhesion beyond simple propeptide removal.","evidence":"Surface plasmon resonance with anti-D'D3 mAbs, shear-induced platelet aggregation, flow chamber assays","pmids":["22452980"],"confidence":"High","gaps":["Fraction of circulating VWF bearing propeptide in vivo unknown","Whether propeptide dissociation is shear-dependent"]},{"year":2014,"claim":"Knock-in mouse models of A1-domain mutations at two distinct GPIbα contact surfaces demonstrated that the kinetic balance between catch and slip bond regimes dictates the hemostatic-thrombotic boundary, with compensatory double mutations normalizing function.","evidence":"VWF-A1 knock-in mice (I1309V, R1326H, double), intravital microscopy, tail bleeding, flow adhesion","pmids":["25293780"],"confidence":"High","gaps":["How flanking domains (D'D3, A2) modulate catch-slip kinetics in full-length VWF","Whether therapeutic tuning of bond kinetics is feasible"]},{"year":2020,"claim":"BLOC-2 and the exocyst complex were identified as two independent regulators of WPB biogenesis that together control VWF multimer maturation and exocytosis, closing a major gap in the WPB formation pathway.","evidence":"siRNA depletion, reciprocal co-IP of BLOC-2–exocyst, VWF multimer analysis, Endosidin2 pharmacological validation","pmids":["32614949"],"confidence":"High","gaps":["How BLOC-2 mediates endosomal input into WPBs","Whether exocyst 'clamping' is relieved by specific stimulatory signaling"]},{"year":2020,"claim":"VWF was shown to maintain vascular barrier integrity during inflammation by serving as the platform for platelet docking, which delivers Angpt1 to activate endothelial Tie-2 via Cdc42-GEF FGD5, preventing leaks during neutrophil transmigration.","evidence":"Endothelial Tie-2 KO, platelet Angpt1 conditional KO, intravital microscopy, anti-VWF antibody blocking","pmids":["32369573"],"confidence":"High","gaps":["Whether this pathway operates in non-inflamed tissues","Relative contributions of endothelial vs platelet Angpt1"]},{"year":2022,"claim":"VWF A2 domain binding to LRP4 receptor, signaling through αvβ3 integrin, was identified as a mechanism by which VWF promotes vascular smooth muscle cell proliferation and intimal hyperplasia, extending VWF's role beyond hemostasis to vascular remodeling.","evidence":"siRNA against LRP4 and αv integrin, co-IP, proximity ligation assay, VWF-KO mouse arterial injury models","pmids":["33576766"],"confidence":"High","gaps":["Whether A2 domain must be unfolded for LRP4 engagement","Downstream transcriptional targets in VSMC not identified"]},{"year":2024,"claim":"The VWF clearance mechanism was molecularly defined: A1-domain residues K1405–K1408 mediate binding to macrophage LRP1, and endothelial PTP1B was identified as a negative regulator of WPB exocytosis acting through SNAP23 dephosphorylation—completing both clearance and release arms of VWF homeostasis.","evidence":"Alanine mutagenesis of K1405–K1408 with in vivo clearance, BT200 aptamer competition; endothelial PTP1B-KO mice with SNAP23 phosphorylation assays and intravital microscopy","pmids":["38996211","38563147"],"confidence":"High","gaps":["Relative contribution of MGL and SR-AI vs LRP1 to total VWF clearance in humans","Whether PTP1B–SNAP23 axis is targetable therapeutically without off-target effects"]},{"year":null,"claim":"Key unresolved questions include: the structural basis of propeptide-assisted interchain disulfide bonding during multimerization; how VWF intracellularly suppresses Ang-2/VEGFR-2 angiogenic signaling; the in vivo force landscape experienced by individual VWF multimers; and whether the non-hemostatic functions (angiogenesis, VSMC proliferation, barrier maintenance) are therapeutically separable from hemostatic activity.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No high-resolution structure of full-length multimeric VWF","Mechanism of intracellular VWF-mediated angiogenesis suppression undefined","Therapeutic strategies separating hemostatic from non-hemostatic VWF functions not developed"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[9,11,15,28,32]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[9,11,42]},{"term_id":"GO:0140104","term_label":"molecular carrier activity","supporting_discovery_ids":[12,17]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[4,5,18,38]}],"localization":[{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[4,18,27,38,44]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[10,26,36,40,41]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[6,33]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[13,16]}],"pathway":[{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[9,11,12,15,20,22,25,26,32,43]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[4,18,27,38,44]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[13,16,36]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[20,22,25,29,39,42]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[5,6,8,24]}],"complexes":["VWF–FVIII complex","GPIb-IX-V complex (VWF ligand)","Weibel-Palade body"],"partners":["GP1BA","F8","ADAMTS13","LRP1","LRP4","SNAP23","RAB27A","MYRIP"],"other_free_text":[]},"mechanistic_narrative":"VWF is a large multimeric glycoprotein produced by endothelial cells and megakaryocytes that serves as the primary adhesive bridge between platelets and damaged vessel walls under high shear stress and as the plasma carrier and stabilizer of coagulation factor VIII [PMID:9759493, PMID:10881749]. Synthesized as a pre-pro-polypeptide (D1-D2-D'-D3-A1-A2-A3-D4-B-C domains), VWF requires its propeptide (D1-D2) as an intramolecular chaperone for disulfide-linked multimerization in the ER, after which furin cleaves the propeptide; ultra-large multimers are stored in endothelial Weibel-Palade bodies—organelles whose biogenesis depends on VWF itself and accessory machinery including BLOC-2, the exocyst complex, and Rab27a/MyRIP—and are released upon stimulation to form platelet-catching strings whose size is homeostatically regulated by shear-dependent A2-domain unfolding and ADAMTS13 cleavage, itself modulated by chloride binding, N-glycosylation at N1574, and thrombospondin-1 competition [PMID:3500851, PMID:2251280, PMID:15331450, PMID:32614949, PMID:19498171, PMID:16899464, PMID:17975018]. The A1 domain mediates GPIbα catch-slip bond adhesion—regulated allosterically by propeptide binding to D'D3 and by A1-domain conformational state—activating platelet signaling through Lyn–cGMP and Lyn/Syk/Btk–TxA₂ cascades, while the A3 domain engages fibrillar collagen at its hydrophobic front surface [PMID:8565074, PMID:12183630, PMID:22452980, PMID:15941906, PMID:16788103, PMID:12447349]. Beyond hemostasis, VWF restrains endothelial angiogenesis via VEGFR-2 and Ang-2, promotes vascular smooth muscle cell proliferation through an A2–LRP4–αvβ3 axis, maintains endothelial barrier integrity during neutrophil extravasation via platelet-derived Angpt1–Tie-2 signaling, and is cleared from plasma by macrophage/Kupffer cell LRP1 through A1-domain residues K1405–K1408 [PMID:21048155, PMID:33576766, PMID:32369573, PMID:38996211]."},"prefetch_data":{"uniprot":{"accession":"P04275","full_name":"von Willebrand factor","aliases":[],"length_aa":2813,"mass_kda":309.3,"function":"Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma","subcellular_location":"Secreted; Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/P04275/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/VWF","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/VWF","total_profiled":1310},"omim":[{"mim_id":"621107","title":"HEMICENTIN 2; HMCN2","url":"https://www.omim.org/entry/621107"},{"mim_id":"620865","title":"EHLERS-DANLOS SYNDROME, CLASSIC-LIKE, 3; EDSCLL3","url":"https://www.omim.org/entry/620865"},{"mim_id":"620776","title":"THROMBOCYTOPENIA 13, SYNDROMIC; THC13","url":"https://www.omim.org/entry/620776"},{"mim_id":"620715","title":"BLEEDING DISORDER, VASCULAR-TYPE; BDVAS","url":"https://www.omim.org/entry/620715"},{"mim_id":"620144","title":"CACHE DOMAIN-CONTAINING PROTEIN 1; CACHD1","url":"https://www.omim.org/entry/620144"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/VWF"},"hgnc":{"alias_symbol":[],"prev_symbol":["F8VWF"]},"alphafold":{"accession":"P04275","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P04275","model_url":"https://alphafold.ebi.ac.uk/files/AF-P04275-2-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P04275-2-F1-predicted_aligned_error_v6.png","plddt_mean":75.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=VWF","jax_strain_url":"https://www.jax.org/strain/search?query=VWF"},"sequence":{"accession":"P04275","fasta_url":"https://rest.uniprot.org/uniprotkb/P04275.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P04275/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P04275"}},"corpus_meta":[{"pmid":"3874428","id":"PMC_3874428","title":"Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization.","date":"1985","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/3874428","citation_count":415,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3019665","id":"PMC_3019665","title":"Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit.","date":"1986","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/3019665","citation_count":241,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16788103","id":"PMC_16788103","title":"Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16788103","citation_count":122,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3500851","id":"PMC_3500851","title":"Expression of variant von Willebrand factor (vWF) cDNA in heterologous cells: requirement of the pro-polypeptide in vWF multimer formation.","date":"1987","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/3500851","citation_count":115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11583318","id":"PMC_11583318","title":"Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen.","date":"2001","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/11583318","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15941906","id":"PMC_15941906","title":"A critical role for 14-3-3zeta protein in regulating the VWF binding function of platelet glycoprotein Ib-IX and its therapeutic implications.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15941906","citation_count":103,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28428179","id":"PMC_28428179","title":"ADAMTS13 controls vascular remodeling by modifying VWF reactivity during stroke recovery.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28428179","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19270261","id":"PMC_19270261","title":"Rab27a and MyRIP regulate the amount and multimeric state of VWF released from endothelial cells.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19270261","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16176307","id":"PMC_16176307","title":"Platelet-derived VWF-cleaving metalloprotease ADAMTS-13.","date":"2005","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/16176307","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23289969","id":"PMC_23289969","title":"The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension.","date":"2013","source":"Clinical and experimental hypertension (New York, N.Y. : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/23289969","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18550847","id":"PMC_18550847","title":"Src family tyrosine kinase Lyn mediates VWF/GPIb-IX-induced platelet activation via the cGMP signaling pathway.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18550847","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31248335","id":"PMC_31248335","title":"Plasma Peptidylarginine Deiminase IV Promotes VWF-Platelet String Formation and Accelerates Thrombosis After Vessel Injury.","date":"2019","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/31248335","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17975018","id":"PMC_17975018","title":"N-linked glycosylation of VWF modulates its interaction with ADAMTS13.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17975018","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33893632","id":"PMC_33893632","title":"Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis.","date":"2021","source":"Seminars in thrombosis and hemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/33893632","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22712744","id":"PMC_22712744","title":"ADAMTS13 reduces VWF-mediated acute inflammation following focal cerebral ischemia in mice.","date":"2012","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/22712744","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26600266","id":"PMC_26600266","title":"Role of fluid shear stress in regulating VWF structure, function and related blood disorders.","date":"2015","source":"Biorheology","url":"https://pubmed.ncbi.nlm.nih.gov/26600266","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7620154","id":"PMC_7620154","title":"Identification of two mutations (Arg611Cys and Arg611His) in the A1 loop of von Willebrand factor (vWF) responsible for type 2 von Willebrand disease with decreased platelet-dependent function of vWF.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7620154","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12447349","id":"PMC_12447349","title":"Collagen-binding mode of vWF-A3 domain determined by a transferred cross-saturation experiment.","date":"2003","source":"Nature structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/12447349","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15985541","id":"PMC_15985541","title":"Botrocetin/VWF-induced signaling through GPIb-IX-V produces TxA2 in an alphaIIbbeta3- and aggregation-independent manner.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15985541","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34053187","id":"PMC_34053187","title":"ADAMTS13 regulation of VWF multimer distribution in severe COVID-19.","date":"2021","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/34053187","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27069929","id":"PMC_27069929","title":"Levels of Serum 25(OH)VD3, HIF-1α, VEGF, vWf, and IGF-1 and Their Correlation in Type 2 Diabetes Patients with Different Urine Albumin Creatinine Ratio.","date":"2016","source":"Journal of diabetes research","url":"https://pubmed.ncbi.nlm.nih.gov/27069929","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21810271","id":"PMC_21810271","title":"Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels.","date":"2011","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21810271","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12176890","id":"PMC_12176890","title":"The role of the D1 domain of the von Willebrand factor propeptide in multimerization of VWF.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12176890","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35875995","id":"PMC_35875995","title":"Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction.","date":"2022","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/35875995","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15331450","id":"PMC_15331450","title":"Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15331450","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9869174","id":"PMC_9869174","title":"von Willebrand factor (vWf) as a plasma marker of endothelial activation in diabetes: improved reliability with parallel determination of the vWf propeptide (vWf:AgII).","date":"1998","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/9869174","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10881749","id":"PMC_10881749","title":"Role of activation of the coagulation factor VIII in interaction with vWf, phospholipid, and functioning within the factor Xase complex.","date":"1999","source":"Trends in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10881749","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2425450","id":"PMC_2425450","title":"Application of an enzyme-linked immunosorbent assay (ELISA) to von Willebrand factor (vWF) and its derivatives.","date":"1986","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/2425450","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23433535","id":"PMC_23433535","title":"Increased VWF antigen levels and decreased ADAMTS13 activity in preeclampsia.","date":"2013","source":"Hematology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/23433535","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32369573","id":"PMC_32369573","title":"Platelets docking to VWF prevent leaks during leukocyte extravasation by stimulating Tie-2.","date":"2020","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/32369573","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12765843","id":"PMC_12765843","title":"Expression of human factor VIII under control of the platelet-specific alphaIIb promoter in megakaryocytic cell line as well as storage together with VWF.","date":"2003","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12765843","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8314538","id":"PMC_8314538","title":"Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with operable cervical cancer: influence of surgical-pathological stage, tumor size, histologic type, and lymph node status.","date":"1993","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/8314538","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26771163","id":"PMC_26771163","title":"Regulation of VWF expression, and secretion in health and disease.","date":"2016","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/26771163","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15613029","id":"PMC_15613029","title":"The roles of ADP and TXA in botrocetin/VWF-induced aggregation of washed platelets.","date":"2004","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/15613029","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20705333","id":"PMC_20705333","title":"Thrombospondin-1 and ADAMTS13 competitively bind to VWF A2 and A3 domains in vitro.","date":"2010","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/20705333","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16470522","id":"PMC_16470522","title":"Regulated release of VWF and FVIII and the biologic implications.","date":"2006","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16470522","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30655285","id":"PMC_30655285","title":"The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension.","date":"2019","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/30655285","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35644028","id":"PMC_35644028","title":"The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies.","date":"2022","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/35644028","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20713003","id":"PMC_20713003","title":"The mechanism of VWF-mediated platelet GPIbalpha binding.","date":"2010","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/20713003","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30355099","id":"PMC_30355099","title":"Extracellular Vimentin/VWF (von Willebrand Factor) Interaction Contributes to VWF String Formation and Stroke Pathology.","date":"2018","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/30355099","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24252058","id":"PMC_24252058","title":"Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.","date":"2013","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/24252058","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33507292","id":"PMC_33507292","title":"Conformation-dependent blockage of activated VWF improves outcomes of traumatic brain injury in mice.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33507292","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25185554","id":"PMC_25185554","title":"Misfolding of vWF to pathologically disordered conformations impacts the severity of von Willebrand disease.","date":"2014","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/25185554","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27543438","id":"PMC_27543438","title":"Intron retention resulting from a silent mutation in the VWF gene that structurally influences the 5' splice site.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/27543438","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17371490","id":"PMC_17371490","title":"A common 253-kb deletion involving VWF and TMEM16B in German and Italian patients with severe von Willebrand disease type 3.","date":"2007","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/17371490","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33974165","id":"PMC_33974165","title":"Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance.","date":"2021","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/33974165","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33556175","id":"PMC_33556175","title":"Impaired adhesion of neutrophils expressing Slc44a2/HNA-3b to VWF protects against NETosis under venous shear rates.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33556175","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35316498","id":"PMC_35316498","title":"COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm.","date":"2022","source":"International journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/35316498","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34752601","id":"PMC_34752601","title":"Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34752601","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27319744","id":"PMC_27319744","title":"Vps33b regulates Vwf-positive vesicular trafficking in megakaryocytes.","date":"2016","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27319744","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22452980","id":"PMC_22452980","title":"von Willebrand factor (VWF) propeptide binding to VWF D'D3 domain attenuates platelet activation and adhesion.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22452980","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37387563","id":"PMC_37387563","title":"Small Extracellular Vesicle-Derived vWF Induces a Positive Feedback Loop between Tumor and Endothelial Cells to Promote Angiogenesis and Metastasis in Hepatocellular Carcinoma.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/37387563","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34505883","id":"PMC_34505883","title":"Plasma and rhADAMTS13 reduce trauma-induced organ failure by restoring the ADAMTS13-VWF axis.","date":"2021","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/34505883","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29207192","id":"PMC_29207192","title":"Resveratrol attenuates hydrogen peroxide‑induced apoptosis, reactive oxygen species generation, and PSGL‑1 and VWF activation in human umbilical vein endothelial cells, potentially via MAPK signalling pathways.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/29207192","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11776320","id":"PMC_11776320","title":"Crotalin, a vWF and GP Ib cleaving metalloproteinase from venom of Crotalus atrox.","date":"2001","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/11776320","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33576766","id":"PMC_33576766","title":"The VWF/LRP4/αVβ3-axis represents a novel pathway regulating proliferation of human vascular smooth muscle cells.","date":"2022","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/33576766","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31905240","id":"PMC_31905240","title":"Low VWF levels in children and lack of association with bleeding in children undergoing tonsillectomy.","date":"2020","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/31905240","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12969981","id":"PMC_12969981","title":"Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12969981","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33301925","id":"PMC_33301925","title":"Emerging mechanisms to modulate VWF release from endothelial cells.","date":"2020","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/33301925","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29299165","id":"PMC_29299165","title":"GATA3-induced vWF upregulation in the lung adenocarcinoma vasculature.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29299165","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32614949","id":"PMC_32614949","title":"VWF maturation and release are controlled by 2 regulators of Weibel-Palade body biogenesis: exocyst and BLOC-2.","date":"2020","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/32614949","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34134470","id":"PMC_34134470","title":"The GPIbα intracellular tail - role in transducing VWF- and collagen/GPVI-mediated signaling.","date":"2022","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/34134470","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30064978","id":"PMC_30064978","title":"A factor VIII-nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation.","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/30064978","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35094008","id":"PMC_35094008","title":"Hyperglycemia-induced oxidative stress promotes tumor metastasis by upregulating vWF expression in endothelial cells through the transcription factor GATA1.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35094008","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27480067","id":"PMC_27480067","title":"HMGB1 facilitates hypoxia-induced vWF upregulation through TLR2-MYD88-SP1 pathway.","date":"2016","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27480067","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23278112","id":"PMC_23278112","title":"Immunoexpression of RANK, RANKL, OPG, VEGF, and vWF in radicular and dentigerous cysts.","date":"2012","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23278112","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28804845","id":"PMC_28804845","title":"Laboratory Testing for von Willebrand Factor Collagen Binding (VWF:CB).","date":"2017","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/28804845","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28804846","id":"PMC_28804846","title":"Laboratory Testing for von Willebrand Factor Ristocetin Cofactor (VWF:RCo).","date":"2017","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/28804846","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25905473","id":"PMC_25905473","title":"FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25905473","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30571316","id":"PMC_30571316","title":"Molecular Imaging of VWF (von Willebrand Factor) and Platelet Adhesion in Postischemic Impaired Microvascular Reflow.","date":"2018","source":"Circulation. Cardiovascular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/30571316","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33556167","id":"PMC_33556167","title":"von Willebrand factor antigen levels are associated with burden of rare nonsynonymous variants in the VWF gene.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33556167","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28804844","id":"PMC_28804844","title":"Laboratory Testing for von Willebrand Factor Antigen (VWF:Ag).","date":"2017","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/28804844","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33212380","id":"PMC_33212380","title":"ADAMTS13 activity, high VWF and FVIII levels in the pathogenesis of deep vein thrombosis.","date":"2020","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/33212380","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33968738","id":"PMC_33968738","title":"Identification of VWF as a Novel Biomarker in Lung Adenocarcinoma by Comprehensive Analysis.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33968738","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35969769","id":"PMC_35969769","title":"Endothelial VWF is critical for the pathogenesis of vaso-occlusive episode in a mouse model of sickle cell disease.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35969769","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31594977","id":"PMC_31594977","title":"Hemophilia A and B mice, but not VWF-/-mice, display bone defects in congenital development and remodeling after injury.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31594977","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36926331","id":"PMC_36926331","title":"New perspectives on the induction and acceleration of immune-associated thrombosis by PF4 and VWF.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36926331","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22952809","id":"PMC_22952809","title":"PR3 and elastase alter PAR1 signaling and trigger vWF release via a calcium-independent mechanism from glomerular endothelial cells.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22952809","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30824114","id":"PMC_30824114","title":"In Vitro Measurement and Modeling of Platelet Adhesion on VWF-Coated Surfaces in Channel Flow.","date":"2019","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/30824114","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8862946","id":"PMC_8862946","title":"Levels of von Willebrand factor, insulin resistance syndrome, and a common vWF gene polymorphism in non-insulin-dependent (type 2) diabetes mellitus.","date":"1996","source":"Diabetic medicine : a journal of the British Diabetic Association","url":"https://pubmed.ncbi.nlm.nih.gov/8862946","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38996211","id":"PMC_38996211","title":"The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1.","date":"2024","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/38996211","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30361419","id":"PMC_30361419","title":"Unraveling the effect of silent, intronic and missense mutations on VWF splicing: contribution of next generation sequencing in the study of mRNA.","date":"2018","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/30361419","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33362379","id":"PMC_33362379","title":"Association between ADAMTS13 activity-VWF antigen imbalance and the therapeutic effect of HAIC in patients with hepatocellular carcinoma.","date":"2020","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/33362379","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18549909","id":"PMC_18549909","title":"The role of VWF in the immunogenicity of FVIII.","date":"2008","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/18549909","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33219619","id":"PMC_33219619","title":"Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population.","date":"2020","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/33219619","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35143643","id":"PMC_35143643","title":"Single-cell transcriptional analysis of human endothelial colony-forming cells from patients with low VWF levels.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/35143643","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28651990","id":"PMC_28651990","title":"A novel function of vitellogenin subdomain, vWF type D, as a toxin-binding protein in the pufferfish Takifugu pardalis ovary.","date":"2017","source":"Toxicon : official journal of the International Society on Toxinology","url":"https://pubmed.ncbi.nlm.nih.gov/28651990","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34989474","id":"PMC_34989474","title":"rhADAMTS13 reduces oxidative stress by cleaving VWF in ischaemia/reperfusion-induced acute kidney injury.","date":"2022","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/34989474","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7749877","id":"PMC_7749877","title":"Induction of GPIb/IX-vWF receptor-ligand translocation on surface-activated platelets.","date":"1995","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7749877","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30099278","id":"PMC_30099278","title":"Coupling of a specific photoreactive triple-helical peptide to crosslinked collagen films restores binding and activation of DDR2 and VWF.","date":"2018","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/30099278","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27533707","id":"PMC_27533707","title":"Mutations in the D'D3 region of VWF traditionally associated with type 1 VWD lead to quantitative and qualitative deficiencies of VWF.","date":"2016","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/27533707","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16764036","id":"PMC_16764036","title":"[Plasma levels of vWF and NO in patients with metabolic syndrome and their relationship with metabolic disorders].","date":"2006","source":"Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16764036","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16899464","id":"PMC_16899464","title":"Molecular mapping of the chloride-binding site in von Willebrand factor (VWF): energetics and conformational effects on the VWF/ADAMTS-13 interaction.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16899464","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28899852","id":"PMC_28899852","title":"Identification of extant vertebrate Myxine glutinosa VWF: evolutionary conservation of primary hemostasis.","date":"2017","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28899852","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25293780","id":"PMC_25293780","title":"Exploiting the kinetic interplay between GPIbα-VWF binding interfaces to regulate hemostasis and thrombosis.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25293780","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33101888","id":"PMC_33101888","title":"von Willebrand factor promotes platelet-induced metastasis of osteosarcoma through activation of the VWF-GPIb axis.","date":"2020","source":"Journal of bone oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33101888","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38563147","id":"PMC_38563147","title":"Endothelial PTP1B Deletion Promotes VWF Exocytosis and Venous Thromboinflammation.","date":"2024","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/38563147","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34861678","id":"PMC_34861678","title":"Multifaceted pathomolecular mechanism of a VWF large deletion involved in the pathogenesis of severe VWD.","date":"2022","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/34861678","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32196607","id":"PMC_32196607","title":"Association of von Willebrand factor (vWF) expression with lymph node metastasis and hemodynamics in papillary thyroid carcinoma.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32196607","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11418069","id":"PMC_11418069","title":"Increased glomerular Vwf after kidney irradiation is not due to increased biosynthesis or endothelial cell proliferation.","date":"2001","source":"Radiation research","url":"https://pubmed.ncbi.nlm.nih.gov/11418069","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9759493","id":"PMC_9759493","title":"Biochemistry and genetics of von Willebrand factor.","date":"1998","source":"Annual review of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9759493","citation_count":1108,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8565074","id":"PMC_8565074","title":"Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor.","date":"1996","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8565074","citation_count":963,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18854154","id":"PMC_18854154","title":"Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication.","date":"2008","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/18854154","citation_count":787,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14718574","id":"PMC_14718574","title":"The human plasma proteome: a nonredundant list developed by combination of four separate sources.","date":"2004","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/14718574","citation_count":658,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6754744","id":"PMC_6754744","title":"Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells.","date":"1982","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/6754744","citation_count":657,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6336654","id":"PMC_6336654","title":"Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor.","date":"1983","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/6336654","citation_count":489,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12665801","id":"PMC_12665801","title":"Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides.","date":"2003","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/12665801","citation_count":485,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12183630","id":"PMC_12183630","title":"Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain.","date":"2002","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12183630","citation_count":467,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8874190","id":"PMC_8874190","title":"Shear-dependent changes in the three-dimensional structure of human von Willebrand factor.","date":"1996","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8874190","citation_count":460,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3524673","id":"PMC_3524673","title":"Amino acid sequence of human von Willebrand factor.","date":"1986","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3524673","citation_count":451,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2584182","id":"PMC_2584182","title":"Structure of the gene for human von Willebrand factor.","date":"1989","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2584182","citation_count":448,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3087627","id":"PMC_3087627","title":"Inducible secretion of large, biologically potent von Willebrand factor multimers.","date":"1986","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/3087627","citation_count":430,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10607717","id":"PMC_10607717","title":"Evidence of increased angiogenesis in patients with acute myeloid leukemia.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10607717","citation_count":421,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19498171","id":"PMC_19498171","title":"Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor.","date":"2009","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/19498171","citation_count":408,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21048155","id":"PMC_21048155","title":"Endothelial von Willebrand factor regulates angiogenesis.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21048155","citation_count":389,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12871266","id":"PMC_12871266","title":"Von Willebrand factor, platelets and endothelial cell interactions.","date":"2003","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/12871266","citation_count":344,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3121636","id":"PMC_3121636","title":"The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins.","date":"1987","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/3121636","citation_count":335,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22139419","id":"PMC_22139419","title":"New gene functions in megakaryopoiesis and platelet formation.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/22139419","citation_count":332,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25712991","id":"PMC_25712991","title":"von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25712991","citation_count":332,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18347221","id":"PMC_18347221","title":"von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes.","date":"2008","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/18347221","citation_count":330,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2251280","id":"PMC_2251280","title":"Expression of a human proprotein processing enzyme: correct cleavage of the von Willebrand factor precursor at a paired basic amino acid site.","date":"1990","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2251280","citation_count":315,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16985174","id":"PMC_16985174","title":"Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD).","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16985174","citation_count":314,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18985028","id":"PMC_18985028","title":"Hepatitis C virus infection protein network.","date":"2008","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/18985028","citation_count":306,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20231535","id":"PMC_20231535","title":"Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium.","date":"2010","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/20231535","citation_count":295,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2864688","id":"PMC_2864688","title":"Cloning and characterization of two cDNAs coding for human von Willebrand factor.","date":"1985","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2864688","citation_count":284,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17493665","id":"PMC_17493665","title":"The role of von Willebrand factor in thrombus formation.","date":"2007","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/17493665","citation_count":268,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55436,"output_tokens":8102,"usd":0.143919},"stage2":{"model":"claude-opus-4-6","input_tokens":11968,"output_tokens":5766,"usd":0.305985},"total_usd":0.939377,"stage1_batch_id":"msgbatch_01BparvgRZ9S2LMidvaoo86K","stage2_batch_id":"msgbatch_01NkBfv9SVZWthhS7j6mU6G3","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":67990,"output_tokens":10473,"usd":0.180533},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":14862,"output_tokens":5266,"usd":0.30894}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1985,\n      \"finding\": \"VWF is encoded by a large single-copy gene located on chromosome 12p12–12pter; it is expressed in endothelial cells (comprising ~0.3% of endothelial cell mRNA) and serves dual roles as a carrier for factor VIIIC and as a mediator of platelet–vessel wall interaction.\",\n      \"method\": \"cDNA cloning, chromosomal localization by in situ hybridization, Northern blotting\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — foundational cDNA and chromosomal mapping study, highly cited, multiple methods\",\n      \"pmids\": [\"3874428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"The full-length VWF precursor (2813 amino acids) consists of a signal peptide, a pro-sequence (domains D1-D2), and mature VWF with a highly repetitive domain structure (D'-D3-A1-A2-A3-D4-B1-B2-C1-C2); the pro-sequence (von Willebrand Antigen II) is equivalent to the propeptide.\",\n      \"method\": \"Full-length cDNA assembly and in vitro expression; sequencing\",\n      \"journal\": \"The EMBO Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — full-length cDNA sequencing and expression, foundational structural paper, highly cited\",\n      \"pmids\": [\"3019665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"The VWF propeptide (domains D1 and D2) is required for multimerization beyond the dimer stage; deletion of the pro-polypeptide coding sequence from full-length cDNA results in VWF that cannot assemble beyond dimers, demonstrating that the propeptide acts as an intramolecular chaperone to align subunits for N-terminal multimerization.\",\n      \"method\": \"Heterologous expression of deletion mutant VWF cDNA in COS-1 cells; multimer analysis\",\n      \"journal\": \"The EMBO Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with mutagenesis in expression system, highly cited, replicated by later studies\",\n      \"pmids\": [\"3500851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The D1 domain of the VWF propeptide is essential for N-terminal multimerization; a Tyr87Ser mutation in D1 results in dimeric VWF with loss of multimerization and consequent loss of collagen binding, factor VIII binding, and ristocetin-induced platelet binding, while granular storage remains intact.\",\n      \"method\": \"Expression of mutant recombinant VWF; multimer analysis, functional binding assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — expression with mutagenesis plus multiple functional assays\",\n      \"pmids\": [\"12176890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Arg611 in the A1 loop of VWF is critical for platelet-dependent function; Arg611Cys and Arg611His mutations (within exon 28) result in decreased high-molecular-weight multimers and markedly reduced ristocetin- and botrocetin-induced binding to platelets, demonstrating the A1 loop's role in GPIb interaction.\",\n      \"method\": \"Site-directed mutagenesis of full-length VWF cDNA; transient expression in COS-7 cells; structural and functional characterization\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with functional reconstitution\",\n      \"pmids\": [\"7620154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Ser968 in the VWF A3 domain is required for normal collagen binding; the Ser968Thr mutation abolishes VWF binding to type I and III collagens without affecting multimeric structure or GPIb binding, identifying the A3 domain hydrophobic surface as the collagen-binding site.\",\n      \"method\": \"Site-directed mutagenesis of full-length VWF cDNA; transient expression in COS-7 cells; collagen binding and GPIb binding assays\",\n      \"journal\": \"Thrombosis and Haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis plus functional reconstitution, patient-derived validation\",\n      \"pmids\": [\"11583318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The collagen-binding site of the VWF A3 domain is located on its hydrophobic 'front' surface, which is distinct from the binding site of the integrin α2-I domain despite their shared fold, as determined by transferred cross-saturation NMR on the VWF A3–fibrillar collagen supramolecular complex.\",\n      \"method\": \"NMR transferred cross-saturation (TCS) spectroscopy\",\n      \"journal\": \"Nature Structural Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure-based identification of binding interface with functional context\",\n      \"pmids\": [\"12447349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"VWF is required for Weibel-Palade body (WPB) biogenesis in endothelial cells; expression of wild-type VWF in VWF-null canine endothelial cells re-establishes WPBs that recruit endogenous P-selectin, while VWF multimerization is not necessary for WPB creation but the VWF propeptide is required for WPB formation.\",\n      \"method\": \"Expression of WT and mutant VWF in canine VWD aortic endothelial cells; confocal immunofluorescence; P-selectin co-localization\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO endothelial cell rescue experiment with defined organelle phenotype\",\n      \"pmids\": [\"15331450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"14-3-3ζ binding to GPIbα is required for VWF binding to the platelet receptor GPIb-IX; a membrane-permeable inhibitor of 14-3-3ζ–GPIbα interaction (MPαC) potently inhibits VWF binding to platelets and VWF-mediated platelet adhesion under flow; dephosphorylation of GPIbβ activates VWF binding through 14-3-3ζ interaction with the C-terminal domain of GPIbα.\",\n      \"method\": \"Cell-permeable peptide inhibitor; mutagenesis of 14-3-3ζ binding site; flow adhesion assay; ristocetin agglutination\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — peptide inhibition plus mutagenesis with functional adhesion readout\",\n      \"pmids\": [\"15941906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Botrocetin/VWF-induced GPIb-IX signaling leading to TxA2 production is initiated by Lyn, enhanced by Src, and propagated through Syk, SLP-76, PI3K, PLCγ2, and PKC; LAT and FcRγ-chain are required for granule secretion and aggregation but not TxA2 production; TxA2 production occurs independently of αIIbβ3 and aggregation.\",\n      \"method\": \"Knockout mouse platelets (Lyn, Src, Syk, SLP-76, PLCγ2, LAT, FcRγ); pharmacological inhibitors; botrocetin/VWF stimulation assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with multiple knockout lines defining signaling pathway\",\n      \"pmids\": [\"15985541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Bruton tyrosine kinase (Btk) is downstream of Lyn, Syk, SLP-76, and PI3K, and upstream of ERK1/2, PLCγ2, and PKC in GPIb-IX-mediated signaling; Btk is essential for botrocetin/VWF-induced TxA2 production and GPIb-dependent stable arterial thrombus formation in vivo.\",\n      \"method\": \"Btk-knockout mouse platelets; signaling assays; ferric chloride carotid artery thrombosis model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with in vitro pathway and in vivo thrombosis readout\",\n      \"pmids\": [\"16788103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"N-linked glycan at Asn1574 of VWF sterically and conformationally inhibits ADAMTS13 cleavage; removal of this glycan (by mutagenesis or PNGase F) increases VWF susceptibility to ADAMTS13 proteolysis and allows cleavage in the absence of denaturants; the N-linked glycan at Asn1515 has no such effect.\",\n      \"method\": \"PNGase F digestion; site-directed mutagenesis (N1515A, N1574A) of full-length and A2 domain recombinant VWF; ADAMTS13 cleavage assay; surface plasmon resonance\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis plus in vitro protease assay with binding kinetics\",\n      \"pmids\": [\"17975018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Src family kinase Lyn mediates VWF/GPIb-IX-induced cGMP elevation, which is required for stable platelet adhesion to VWF under shear stress independently of TxA2 synthesis; Lyn-knockout platelets fail to elevate cGMP and display impaired stable adhesion and spreading on VWF (but not fibrinogen); exogenous 8-bromo-cGMP rescues the adhesion defect.\",\n      \"method\": \"Lyn, Fyn knockout mouse platelets; botrocetin/VWF stimulation; shear flow adhesion; cGMP measurement; 8-bromo-cGMP rescue\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple KO lines with rescue experiment defining pathway\",\n      \"pmids\": [\"18550847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Rab27a and its effector MyRIP anchor mature Weibel-Palade bodies to peripheral actin; depletion of either protein leads to loss of peripheral WPB localization, increased basal and stimulated VWF secretion, and release of less-multimerized VWF forming shorter platelet-binding strings under flow.\",\n      \"method\": \"siRNA depletion in primary endothelial cells; live imaging of WPB distribution; flow-based VWF string assay; multimer analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — siRNA knockdown with direct localization and functional secretion readouts\",\n      \"pmids\": [\"19270261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"VWF A1 domain binding to GPIbα is thermodynamically coupled to A1 unfolding; reduction and carboxyamidation of the A1 disulfide bond generates an intermediate conformation with ~20-fold higher GPIbα affinity; catch-to-slip bond behavior under shear reflects equilibrium between these conformational states.\",\n      \"method\": \"Biophysical assays (CD spectroscopy, SPR); thermodynamic modeling; disulfide bond reduction/carboxyamidation\",\n      \"journal\": \"Biophysical Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with multiple biophysical methods defining conformational mechanism\",\n      \"pmids\": [\"20713003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Thrombospondin-1 (TSP1) competitively binds to VWF A2 and A3 domains and inhibits ADAMTS13 binding and cleavage of VWF by up to 70%, revealing a competitive inhibitory mechanism at the A2 and A3 domains.\",\n      \"method\": \"ELISA binding assays with recombinant VWF domains (A1, A2, A3) and ADAMTS13; western blot and residual collagen binding assay for ADAMTS13 cleavage\",\n      \"journal\": \"Thrombosis Research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — in vitro binding and cleavage assays, single lab\",\n      \"pmids\": [\"20705333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"VWF propeptide (VWFpp) binds with high affinity to the D'D3 domain of mature VWF (the only binding site) and this interaction persists in plasma; VWFpp binding reduces VWF-mediated platelet adhesion and shear-induced platelet aggregation, revealing a regulatory mechanism for VWF hemostatic function.\",\n      \"method\": \"Surface plasmon resonance (SPR) kinetics; anti-D'D3 monoclonal antibodies; flow chamber platelet adhesion assays; viscometer shear aggregation\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — SPR kinetics plus functional adhesion assay with blocking antibody, multiple orthogonal methods\",\n      \"pmids\": [\"22452980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Chloride ions bind specifically to the VWF A1 domain (not the A2 domain alone) and allosterically stabilize the folded conformation of A1-A2-A3, inhibiting ADAMTS13 cleavage of the Tyr1605-Met1606 bond in A2; the type 2B VWD mutant R1306W in the A1 domain reduces chloride binding affinity.\",\n      \"method\": \"Urea-induced unfolding with NaCl/NaClO4/acetate; spectroscopy; ADAMTS13 cleavage assay under urea and shear; thermodynamic analysis\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro binding and protease assays with mutagenesis and thermodynamic analysis\",\n      \"pmids\": [\"16899464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The kinetic interplay between two distinct GPIbα contact surfaces on the VWF A1 domain governs platelet adhesion: the major site mutation R1326H shortens bond lifetime and causes hemostatic defects equivalent to VWF deficiency, while the minor site mutation I1309V prolongs bond lifetime causing a type 2B-like phenotype; combining R1326H and I1309V normalizes bond kinetics and hemostatic properties.\",\n      \"method\": \"VWF-A1 knock-in mice (I1309V, R1326H); bond lifetime measurements; hemostatic and thrombosis models; allosteric inhibitor\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — knock-in mouse models with biophysical bond measurements and in vivo phenotyping\",\n      \"pmids\": [\"25293780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A silent (synonymous) mutation c.7464C>T in VWF exon 44 causes intron 44 retention by inducing a stable hairpin in pre-mRNA secondary structure at the 5' splice site (85 bp from the mutation), sequestering U1 snRNA binding residues; the resulting truncated protein accumulates in the ER of patient endothelial cells.\",\n      \"method\": \"RT-PCR transcript analysis; confocal immunofluorescence of patient blood outgrowth endothelial cells; in silico pre-mRNA structure analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — combined transcript analysis, in vivo patient cell imaging, and structural RNA modeling\",\n      \"pmids\": [\"27543438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Extracellular vimentin interacts with the VWF A2 domain to tether VWF strings to the endothelial surface; blocking this interaction with recombinant A2 domain protein or anti-vimentin antibodies reduces VWF string formation; vimentin knockout mice show reduced cerebral VWF strings; A2 protein treatment improves cortical reperfusion after ischemic stroke.\",\n      \"method\": \"Recombinant A2 domain blocking experiments; anti-vimentin antibodies; vimentin KO mice; histamine stimulation; laser speckle contrast imaging; transient middle cerebral artery occlusion model\",\n      \"journal\": \"Stroke\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse, recombinant protein blocking, and in vivo functional imaging, multiple orthogonal methods\",\n      \"pmids\": [\"30355099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Extracellular PAD4 citrullinates ADAMTS13 on specific arginine residues, dramatically inhibiting ADAMTS13 enzymatic activity and thereby preventing clearance of VWF-platelet strings; in vivo injection of PAD4 induces VWF-platelet string formation and accelerates thrombus formation in a PAD4 enzymatic activity-dependent manner.\",\n      \"method\": \"In vivo PAD4 injection; mass spectrometry identification of citrullination sites; in vitro ADAMTS13 activity assay; Adamts13-/- mouse model; ferric chloride mesenteric venule injury\",\n      \"journal\": \"Circulation Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — MS-identified PTM sites, in vitro activity assay, and in vivo rescue/phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"31248335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BLOC-2 mediates endolysosomal trafficking to supply cargo-carrying transport tubules for WPB maturation; exocyst complex binds BLOC-2 and clamps WPB release; depletion of either impairs high-molecular-weight VWF in releasates; exocyst-depleted cells paradoxically increase WPB exocytosis, and a small molecule inhibitor of exocyst reversibly augments secretion of mature WPBs.\",\n      \"method\": \"siRNA depletion in endothelial cells; immunoprecipitation of BLOC-2/exocyst; WPB morphology; VWF multimer analysis; Endosidin2 pharmacological inhibition\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus siRNA KD with multiple functional readouts\",\n      \"pmids\": [\"32614949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Platelets interacting with endothelial VWF prevent vascular leaks during neutrophil diapedesis by secreting angiopoietin-1 (Angpt1), which activates Tie-2 on endothelial cells; blocking VWF results in vascular leaks during neutrophil transmigration.\",\n      \"method\": \"VWF blocking antibodies; Tie-2 knockout mice; neutrophil depletion; FGD5 silencing; intravital fluorescence microscopy of cremaster venules\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and antibody-blocking experiments with intravital imaging readout\",\n      \"pmids\": [\"32369573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Slc44a2/HNA-3a on neutrophils acts as a receptor for VWF mediating neutrophil adhesion under venous shear; HNA-3b expression impairs this adhesion; Slc44a2-knockout mice show markedly reduced neutrophil recruitment in inflamed venules, linking neutrophil-VWF interaction to venous thrombosis risk.\",\n      \"method\": \"Flow chamber adhesion assays with transfected HEK293T cells and human donor neutrophils; intravital microscopy in Slc44a2-KO mice; histamine-stimulated endothelial degranulation\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with intravital imaging and in vitro flow assay, multiple orthogonal methods\",\n      \"pmids\": [\"33556175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The VWF A1 domain is exposed and hyperadhesive on VWF released during acute traumatic brain injury; selective blockade of this A1 domain using a recombinant VWF A2-domain protein prevents TBI-induced coagulopathy, reduces platelet activation and microvesiculation, and improves neurological outcomes in mice.\",\n      \"method\": \"Recombinant A2 domain protein; TBI mouse model (lateral fluid percussion); platelet activation assays; coagulation assays; functional neurological scoring\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — targeted domain blocking with in vivo functional and mechanistic readouts\",\n      \"pmids\": [\"33507292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"VWF mediates vascular smooth muscle cell (VSMC) proliferation through its A2 domain binding to the LRP4 receptor, which co-localizes and co-immunoprecipitates with αvβ3 integrin; VWF-deficient mice show reduced hyperplasia in carotid artery ligation and femoral denudation models.\",\n      \"method\": \"siRNA against αv integrin and LRP4; RGT-peptide blocking; confocal fluorescence; proximity ligation analysis; immunoprecipitation; VWF-deficient mouse arterial injury models\",\n      \"journal\": \"Cardiovascular Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus KO mouse model with defined proliferation phenotype\",\n      \"pmids\": [\"33576766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Endothelial PTP1B suppresses VWF exocytosis by dephosphorylating SNAP23; deletion of endothelial PTP1B increases SNAP23 phosphorylation, enhancing WPB exocytosis and neutrophil adhesion, leading to venous thromboinflammation; anti-VWF antibodies abolish neutrophil adhesion in PTP1B-KO endothelial cells.\",\n      \"method\": \"Inducible endothelial PTP1B-KO mice; inferior vena cava ligation; SNAP23 phosphorylation analysis; VWF-blocking antibodies; intravital microscopy\",\n      \"journal\": \"Circulation Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined molecular mechanism (SNAP23 phosphorylation) and in vivo phenotype\",\n      \"pmids\": [\"38563147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"The cluster of lysines K1405–K1408 in the VWF A1 domain mediates VWF binding to macrophage LRP1 (clusters II and IV), macrophage galactose lectin, and SR-AI scavenger receptor; alanine mutagenesis of this cluster reduces VWF clearance in vivo; the aptamer BT200 (rondaptivon pegol) prolongs VWF half-life by blocking this interaction.\",\n      \"method\": \"Alanine mutagenesis (VWF-4A); LRP1 binding assays; HEK-LRP1 cell binding; in vivo clearance studies; BT200 blocking experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis with in vitro binding and in vivo clearance validation, multiple receptor targets tested\",\n      \"pmids\": [\"38996211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Factor VIII is co-stored with VWF in megakaryocyte α-granules when FVIII is directed to megakaryocyte synthesis; VWF serves as a carrier for FVIII in the regulated secretory pathway.\",\n      \"method\": \"Megakaryocytic cell line (Dami) transfection with αIIb-promoter-driven FVIII cDNA; immunofluorescence co-localization of FVIII and VWF; FVIII activity assay\",\n      \"journal\": \"Molecular Genetics and Metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single transfection/co-localization experiment in cell line\",\n      \"pmids\": [\"12765843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Factor VIII circulates in plasma as a complex with VWF; upon thrombin or factor Xa activation, FVIII dissociates from VWF via cleavage within the light chain releasing a 40-amino-acid N-terminal peptide, inducing a conformational change in the C2 domain that increases phospholipid binding affinity and enables assembly of the factor Xase complex.\",\n      \"method\": \"Review synthesizing biochemical activation experiments, phospholipid binding assays, and Xase complex reconstitution\",\n      \"journal\": \"Trends in Cardiovascular Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review paper synthesizing mechanistic data from multiple labs; underlying experiments are Tier 1 but the paper itself is a review\",\n      \"pmids\": [\"10881749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Vps33b regulates VWF-positive vesicular trafficking in megakaryocytes; haematopoietic stem cell-specific Vps33b deletion abolishes platelet α-granules; VPS33B associates with VIPAS39, α-tubulin, and SEC22B (by co-IP); Vps33b deficiency disrupts co-localization of Sec22b with VWF-positive vesicles, impairing VWF trafficking to α-granule vacuoles.\",\n      \"method\": \"Tamoxifen-induced HSC-specific Vps33b KO mice; co-immunoprecipitation; pulldown; immunoblotting; confocal co-localization\",\n      \"journal\": \"The Journal of Pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with defined organelle phenotype plus Co-IP binding partners\",\n      \"pmids\": [\"27319744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Endothelial VWF is critical for vaso-occlusion in sickle cell disease; endothelial-specific VWF deletion decreases hemolysis, vascular occlusion, and organ damage in TNF-induced vaso-occlusive episodes in humanized SCD mice; administration of ADAMTS13 reduces plasma VWF levels and alleviates vaso-occlusion.\",\n      \"method\": \"Endothelial-specific VWF KO mice in humanized SCD background; TNF-induced VOE model; ADAMTS13 infusion; histological and plasma biomarker analysis\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific KO with rescue by ADAMTS13, defined pathological readout\",\n      \"pmids\": [\"35969769\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"VWF is synthesized as a large pre-pro-polypeptide in endothelial cells and megakaryocytes; its propeptide (D1-D2) acts as an intramolecular chaperone essential for N-terminal multimerization and Weibel-Palade body biogenesis (with Rab27a/MyRIP anchoring mature WPBs to peripheral actin and BLOC-2/exocyst controlling WPB maturation and clamped release); the mature protein carries factor VIII in plasma (protecting it from clearance via a VWF D'D3-binding interaction, with macrophage LRP1 recognizing a K1405-K1408 cluster in the A1 domain to mediate VWF clearance), mediates platelet tethering under shear via a conformationally regulated A1-domain/GPIbα catch-to-slip bond (modulated by 14-3-3ζ, chloride binding, and A1 disulfide status), initiates intracellular signaling through GPIb-IX via a Lyn→Syk→SLP-76→PI3K→Btk→PLCγ2/PKC/cGMP cascade, and anchors VWF strings to the endothelial surface through an A2 domain–vimentin interaction; ADAMTS13 cleaves the A2-domain Tyr1605-Met1606 bond to limit ultralarge multimer accumulation, a process modulated by N-glycosylation at Asn1574, chloride-induced allosteric stabilization, PAD4-mediated citrullination of ADAMTS13, and competitive binding of TSP1 and platelet factor 4; additionally, VWF promotes VSMC proliferation via A2-domain binding to LRP4/αvβ3, and regulates venous thromboinflammation by supporting neutrophil adhesion through Slc44a2 and platelet-derived Angpt1/Tie-2 signaling.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1985,\n      \"finding\": \"VWF cDNA clones spanning 8.2 kb of mRNA were isolated from human endothelial cells; the VWF gene was localized to chromosome 12p12-12pter, and VWF accounts for ~0.3% of endothelial cell mRNA.\",\n      \"method\": \"cDNA library screening, chromosomal localization by in situ hybridization\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cDNA cloning with chromosomal mapping, foundational paper with 415 citations\",\n      \"pmids\": [\"3874428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"VWF cDNA encodes a precursor protein with a signal peptide, propeptide, and mature subunit; the carboxyl-terminal portion contains internal gene duplications and the cell-attachment tetrapeptide Arg-Gly-Asp-Ser.\",\n      \"method\": \"cDNA cloning and sequencing, amino acid sequence comparison\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct cDNA sequencing with protein sequence validation, foundational paper\",\n      \"pmids\": [\"2864688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"Full-length VWF cDNA encodes a single-chain precursor of 2813 amino acids with a signal peptide (22 aa), prosequence (741 aa, domains D1-D2), and mature VWF (2050 aa); the domain structure is D1-D2-D'-D3-A1-A2-A3-D4-B1-B2-C1-C2; in vitro expression confirmed synthesis of the unglycosylated precursor.\",\n      \"method\": \"Full-length cDNA assembly and in vitro expression in COS-1 cells\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — complete cDNA sequencing plus in vitro expression, 241 citations\",\n      \"pmids\": [\"3019665\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"The amino acid sequence of mature VWF (2050 residues) was determined; it contains 12 Asn-linked and 10 Thr/Ser-linked oligosaccharide chains, and shows homology to complement factor B.\",\n      \"method\": \"Direct protein sequencing (Edman degradation) combined with cDNA-derived sequence\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — complete protein sequencing with carbohydrate site mapping, 451 citations\",\n      \"pmids\": [\"3524673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"VWF is localized to Weibel-Palade bodies in human endothelial cells; constitutively secreted VWF is predominantly dimeric with pro-VWF subunits, whereas inducible secretion (by thrombin or calcium ionophore) releases only very large multimers of mature subunits that are more active in platelet binding.\",\n      \"method\": \"Immunofluorescence, immunoperoxidase/electron microscopy, stimulated secretion assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct organelle localization plus functional characterization of two secretory pathways, 430 and 657 citations across two key papers\",\n      \"pmids\": [\"3087627\", \"6754744\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"The VWF propeptide (domains D1-D2) is required for multimerization beyond the dimer stage: COS-1 cells expressing a propeptide-deleted VWF cDNA produce only dimers, demonstrating that dimerization is propeptide-independent but multimerization requires the propeptide.\",\n      \"method\": \"Heterologous expression of full-length and propeptide-deleted VWF cDNA in COS-1 cells\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct mutagenesis and expression showing propeptide requirement for multimerization, 115 citations\",\n      \"pmids\": [\"3500851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"N-linked glycosylation of VWF is required for efficient secretion; VWF transiently associates with BiP (heavy chain-binding protein) during biosynthesis in CHO cells, and this association dissipates as the protein is glycosylated and secreted.\",\n      \"method\": \"Tunicamycin treatment, co-immunoprecipitation of BiP with VWF in CHO cells\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — co-IP and chemical inhibition showing BiP–VWF association dependent on glycosylation state, 335 citations\",\n      \"pmids\": [\"3121636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"The VWF gene spans ~178 kb and contains 52 exons (40 bp to 1379 bp); the signal peptide and propeptide are encoded by 17 exons in ~80 kb, and the mature subunit by 35 exons in ~100 kb; domain-encoding exon structure supports origin by gene segment duplication.\",\n      \"method\": \"Cosmid library screening, restriction mapping, complete sequencing of exon-intron boundaries\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — complete gene structure determination, 448 citations\",\n      \"pmids\": [\"2584182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"PACE (Paired basic Amino acid Cleaving Enzyme, later furin) cleaves the VWF propeptide at the paired basic amino acid site (Arg-Ser cleavage site); co-expression of PACE with VWF in COS-1 cells enhanced propeptide processing.\",\n      \"method\": \"cDNA cloning of PACE, co-expression with VWF precursor in COS-1 cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution of propeptide cleavage by identified enzyme in cells, 315 citations\",\n      \"pmids\": [\"2251280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"GPIbα binding to immobilized VWF supports fast-on/fast-off platelet tethering and translocation at shear rates >6000 s⁻¹; this mechanism allows subsequent αIIbβ3 activation and firm arrest on VWF, coupling two distinct adhesion mechanisms.\",\n      \"method\": \"Flow chamber assays with defined shear rates, blocking antibodies and glycoprotein-deficient platelets\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — rigorous flow-based functional assay demonstrating two-step platelet adhesion mechanism, 963 citations\",\n      \"pmids\": [\"8565074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"VWF undergoes a shear-stress-induced conformational transition from a globular (~149×77 nm) to an extended chain conformation at a critical shear stress of ~35 dyn/cm², with exposure of intramolecular globular domains; this structural change is directional, aligned with shear.\",\n      \"method\": \"Atomic force microscopy of VWF on hydrophobic surfaces under defined shear stress\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct structural imaging under controlled shear, 460 citations\",\n      \"pmids\": [\"8874190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"VWF mediates platelet adhesion through binding to platelet GPIb and to subendothelial connective tissue components; VWF also serves as carrier for factor VIII, protecting it from proteolytic degradation; VWF multimer size is regulated by ADAMTS13-like proteolysis and allosteric mechanisms involving hydrodynamic shear.\",\n      \"method\": \"Comprehensive biochemical review synthesizing purification, binding, and mutagenesis data\",\n      \"journal\": \"Annual review of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — synthesis of multiple reconstitution and structural studies, 1108 citations\",\n      \"pmids\": [\"9759493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Non-activated FVIII circulates in a complex with VWF; upon thrombin- or FXa-mediated activation, FVIII dissociates from VWF with concomitant conformational change in the C2 domain, dramatically increasing FVIII affinity for phospholipid surfaces and enabling factor Xase complex assembly.\",\n      \"method\": \"In vitro proteolysis, binding assays with phospholipid vesicles, domain mutagenesis\",\n      \"journal\": \"Trends in cardiovascular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mechanistic dissection of FVIII–VWF dissociation and Xase assembly using biochemical reconstitution\",\n      \"pmids\": [\"10881749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The A3 domain of VWF mediates collagen binding; a Ser968Thr substitution in the A3 domain abolishes collagen binding while preserving VWF multimeric structure and GPIb binding, identifying Ser968 as critical for collagen interaction.\",\n      \"method\": \"Site-directed mutagenesis of full-length VWF cDNA, transient expression in COS-7 cells, collagen binding assays\",\n      \"journal\": \"Thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with functional validation in recombinant system, confirmed in patient plasma\",\n      \"pmids\": [\"11583318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The D1 domain of the VWF propeptide is critical for N-terminal multimerization; a Tyr87Ser mutation in D1 results in predominantly dimeric VWF with loss of collagen binding, factor VIII binding, and ristocetin-induced platelet binding, but normal granular storage, indicating the propeptide acts as an intramolecular chaperone for multimerization.\",\n      \"method\": \"Patient mutation identification, recombinant VWF expression, multimer analysis, functional binding assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — patient mutation, recombinant expression and multiple orthogonal functional assays\",\n      \"pmids\": [\"12176890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Crystal structures of GPIbα amino-terminal domain and its complex with VWF A1 domain revealed that GPIbα wraps around one side of A1 at two contact areas bridged by solvated charge interactions; gain-of-function mutations in bleeding disorders map to these interfaces.\",\n      \"method\": \"X-ray crystallography of GPIbα alone and GPIbα–VWF A1 complex\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with direct functional mapping, 467 citations\",\n      \"pmids\": [\"12183630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The collagen-binding site of the VWF A3 domain is located on its hydrophobic 'front' surface, as determined by transferred cross-saturation NMR; this binding surface is distinct from the 'top' surface used by the integrin α2-I domain despite shared fold and function.\",\n      \"method\": \"Transferred cross-saturation NMR on A3 domain–fibrillar collagen complex\",\n      \"journal\": \"Nature structural biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR method providing atomic-resolution contact map, validated against structural homolog\",\n      \"pmids\": [\"12447349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"VWF–FVIII complex bound with VWF is cleared predominantly by Kupffer cells/macrophages in the liver; free FVIII unbound from VWF is cleared by hepatocytes via a VWF-independent pathway.\",\n      \"method\": \"Pharmacokinetic studies, immunohistochemistry in VWF-null mice, FcRn chimeric mice\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo biodistribution with immunohistochemistry in multiple mouse models\",\n      \"pmids\": [\"25905473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"VWF is essential for Weibel-Palade body (WPB) biogenesis in endothelial cells; re-expression of wild-type VWF in VWF-null canine aortic endothelial cells restored WPBs that recruited endogenous P-selectin; VWF multimerization is not required for WPB creation, but the propeptide alone cannot independently induce granule formation.\",\n      \"method\": \"Canine VWD endothelial cell model, lentiviral re-expression, confocal immunofluorescence\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — VWF-null endothelial cell reconstitution with multiple VWF mutants and direct organelle imaging\",\n      \"pmids\": [\"15331450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"14-3-3ζ binding to the cytoplasmic tail of GPIbα (and GPIbβ) regulates the VWF-binding function of the GPIb-IX complex; a membrane-permeable inhibitor of 14-3-3ζ–GPIbα interaction potently inhibited VWF binding to platelets and VWF-mediated platelet adhesion under flow.\",\n      \"method\": \"Membrane-permeable inhibitor peptide, mutagenesis of 14-3-3ζ binding site in GPIbβ, flow adhesion assays, ristocetin agglutination\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic disruption of 14-3-3ζ interaction with defined functional readout\",\n      \"pmids\": [\"15941906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"GPIb-IX-mediated botrocetin/VWF agglutination triggers TxA2 production via a signaling cascade initiated by Lyn, enhanced by Src, and propagated through Syk, SLP-76, PI3K, PLCγ2, and PKC; LAT and FcRγ-chain are not required for TxA2 production but are required for granule secretion.\",\n      \"method\": \"Genetic knockout mouse platelets (Lyn, Src, Syk, SLP-76, PLCγ2, LAT, FcRγ), pharmacological inhibitors, wortmannin\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic epistasis analysis using multiple knockout mouse lines\",\n      \"pmids\": [\"15985541\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Platelets contain functionally active ADAMTS13 on their surface; platelet ADAMTS13 activity increases upon thrombin receptor-activating peptide (but not ADP) stimulation, and can cleave endothelial-derived ultra-large VWF multimers under static and flow conditions.\",\n      \"method\": \"Platelet lysate VWF cleavage assays, ADAMTS13 antibody inhibition, flow cytometry for surface ADAMTS13\",\n      \"journal\": \"Journal of thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple antibodies against different ADAMTS13 domains, functional cleavage assays with inhibition controls\",\n      \"pmids\": [\"16176307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Bruton tyrosine kinase (Btk) is required for GPIb-mediated VWF-induced platelet signaling leading to TxA2 production; Btk acts downstream of Lyn, Syk, SLP-76, and PI3K, and upstream of ERK1/2, PLCγ2, and PKC; Btk is also essential for GPIb-dependent arterial thrombus formation in vivo.\",\n      \"method\": \"Btk-knockout and Tec-knockout mouse platelets, ferric chloride carotid artery injury model, kinase inhibitors\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO epistasis placing Btk in signaling pathway, confirmed in vivo thrombosis model\",\n      \"pmids\": [\"16788103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Chloride ions bind specifically to the VWF A1 domain (not A2), stabilizing its folded conformation and allosterically inhibiting ADAMTS13-mediated cleavage of the Tyr1605-Met1606 bond in the A2 domain; the R1306W type 2B VWD mutation reduces chloride affinity for the A1 domain.\",\n      \"method\": \"Urea-induced unfolding spectroscopy, isothermal titration calorimetry, ADAMTS13 cleavage assays with isolated VWF domains\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — thermodynamic and enzymatic characterization with domain-specific mutants identifying allosteric chloride binding site\",\n      \"pmids\": [\"16899464\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"N-linked glycans at VWF residue N1574 (but not N1515) sterically inhibit ADAMTS13-mediated cleavage; removal of N-linked glycans (PNGaseF) increases VWF affinity for ADAMTS13 ~4-fold and allows cleavage without urea denaturation; ABO(H) blood group sugars occupy N1515 and N1574.\",\n      \"method\": \"PNGaseF digestion, site-directed mutagenesis of N-glycosylation sites in recombinant VWF and isolated A2 domain, ADAMTS13 binding/cleavage assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis of specific glycosylation sites with reconstituted cleavage assays\",\n      \"pmids\": [\"17975018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Src family kinase Lyn mediates VWF/GPIb-IX-induced stable platelet adhesion under shear stress via elevation of cGMP independently of TxA2 synthesis; Fyn mediates the TxA2-dependent second wave of aggregation but not stable adhesion; low-concentration 8-bromo-cGMP corrects Lyn-KO adhesion defect.\",\n      \"method\": \"Lyn-KO and Fyn-KO mouse platelets, flow adhesion on VWF, cGMP measurements, 8-bromo-cGMP rescue\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with epistasis, pharmacological rescue with cGMP analog defining pathway\",\n      \"pmids\": [\"18550847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"VWF A2 domain is mechanically unfolded by elongational forces in the physiological range (force proportional to multimer length squared, highest at the center of the multimer); only the unfolded A2 domain is cleaved by ADAMTS13, providing a homeostatic mechanism for size regulation by force-induced cleavage.\",\n      \"method\": \"Single-molecule force spectroscopy (optical tweezers), shear flow experiments, ADAMTS13 cleavage of unfolded A2\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — single-molecule reconstitution demonstrating force-dependent A2 unfolding and ADAMTS13 cleavage, 408 citations\",\n      \"pmids\": [\"19498171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Rab27a and its effector MyRIP anchor mature Weibel-Palade bodies to peripheral actin; depletion of Rab27a or MyRIP increases both basal and stimulated VWF secretion, but the released VWF is less multimerized and VWF strings under flow are shorter, indicating this complex controls peripheral WPB distribution and prevents release of incompletely processed VWF.\",\n      \"method\": \"siRNA depletion in primary endothelial cells, live imaging, WPB localization, VWF multimer analysis, flow-induced string assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — siRNA knockdown with multiple orthogonal functional readouts in primary cells\",\n      \"pmids\": [\"19270261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"VWF A1 domain unfolding from native to intermediate state (reduction of disulfide bond) increases GPIbα binding affinity ~20-fold; A1:GPIbα binding is thermodynamically coupled to A1 unfolding, and catch-to-slip bond transition under shear force is a manifestation of this coupling.\",\n      \"method\": \"Thermodynamic unfolding analysis, circular dichroism, GPIbα binding affinity measurements under reducing conditions\",\n      \"journal\": \"Biophysical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — thermodynamic reconstitution with quantitative allosteric model\",\n      \"pmids\": [\"20713003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"VWF deficiency in endothelial cells (siRNA or VWD patient-derived progenitor cells) causes increased VEGFR-2-dependent proliferation and migration, decreased integrin αvβ3, and increased Ang-2 release, resulting in enhanced angiogenesis; VWF-deficient mice show increased vascularization in vivo.\",\n      \"method\": \"siRNA knockdown in HUVECs, EPC-derived cells from VWD patients, in vitro tube formation, mouse vascularization models\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — siRNA and patient-derived cells with multiple orthogonal readouts in vitro and in vivo, 389 citations\",\n      \"pmids\": [\"21048155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Thrombospondin-1 (TSP1) competitively inhibits ADAMTS13 binding to VWF A2 and A3 domains, blocking ADAMTS13 cleavage by up to 70%; TSP1 also binds A1 domain, whereas ADAMTS13 interacts with all three A domains.\",\n      \"method\": \"ELISA binding assays with recombinant VWF A domains, western blot, residual collagen-binding assay for ADAMTS13 activity\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — binding assays with functional inhibition assay, single lab\",\n      \"pmids\": [\"20705333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"VWF propeptide (VWFpp) binds specifically to the D'D3 domain of mature VWF with high affinity under intracellular (pH 6.2, 10 mM Ca²⁺) conditions (KD = 0.2 nM) and weaker affinity under physiological plasma conditions (KD = 25–50 nM); this persistent binding in circulation attenuates VWF platelet adhesion by reducing GPIbα engagement.\",\n      \"method\": \"Surface plasmon resonance, novel anti-D'D3 mAbs, shear-induced platelet aggregation assays, flow chamber adhesion assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — quantitative binding kinetics by SPR plus functional platelet assays with blocking antibodies\",\n      \"pmids\": [\"22452980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The kinetic interplay between two distinct GPIbα–VWF A1 contact surfaces regulates hemostasis and thrombosis: a mutation enhancing the minor site (I1309V) prolongs bond lifetime and produces type 2B VWD-like thrombocytopenia, while disrupting the major site (R1326H) shortens bond lifetime and produces hemostatic defects comparable to VWF deficiency; combining both mutations normalizes kinetics and function.\",\n      \"method\": \"VWF-A1 knock-in mice (I1309V, R1326H, double mutant), flow chamber assays, intravital microscopy, tail bleeding times\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple knock-in mouse models with in vitro and in vivo functional readouts\",\n      \"pmids\": [\"25293780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A silent mutation (c.7464C>T) in VWF exon 44 causes intron 44 retention by inducing a stable hairpin structure 85 bp upstream of the 5' splice site that sequesters residues required for U1 snRNA interaction, resulting in a truncated VWF protein that accumulates in the endoplasmic reticulum.\",\n      \"method\": \"Patient transcript analysis, in vivo and ex vivo RT-PCR, confocal immunofluorescence of blood outgrowth endothelial cells, in silico pre-mRNA secondary/tertiary structure prediction\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — patient mutation, transcript analysis, protein mislocalization confirmed by immunofluorescence, structural mechanism validated in silico\",\n      \"pmids\": [\"27543438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HMGB1 upregulates VWF expression in vivo through a TLR2–MYD88–SP1 signaling pathway; TLR2 silencing abolishes MYD88 and VWF expression and SP1 phosphorylation, and glycyrrhizic acid or Tlr2 silencing blocks Sp1 binding to the Vwf promoter.\",\n      \"method\": \"Mouse acute hypoxia model, Tlr2 siRNA knockdown, TLR2-neutralizing antibody, SP1 inhibitor, chromatin immunoprecipitation (ChIP) of Sp1 at Vwf promoter\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo knockdown with ChIP validation of promoter binding, single lab\",\n      \"pmids\": [\"27480067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GATA3 mediates upregulation of VWF transcription in lung adenocarcinoma-associated endothelial cells; conditioned medium from A549 cells increases GATA3 binding to a GATA binding motif at +220 of the VWF promoter, as confirmed by ChIP.\",\n      \"method\": \"Co-culture system with conditioned medium, ChIP assay for GATA3 at VWF promoter, siRNA knockdown of GATA3 vs ERG\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirming direct transcription factor binding at VWF promoter with functional siRNA validation\",\n      \"pmids\": [\"29299165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Extracellular vimentin on the endothelial surface binds the VWF A2 domain to tether VWF strings; Vim-KO mouse cerebral arteries produce fewer VWF strings after histamine stimulation, and recombinant A2 protein or anti-vimentin antibodies block VWF string formation; A2 treatment improved cortical reperfusion after stroke in mice.\",\n      \"method\": \"Histamine stimulation of pressurized cerebral arteries, Vim-KO mice, anti-vimentin antibodies, recombinant A2 domain blockade, laser speckle contrast imaging\",\n      \"journal\": \"Stroke\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO plus pharmacological blocking in multiple complementary in vitro and in vivo systems\",\n      \"pmids\": [\"30355099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Extracellular PAD4 citrullinates ADAMTS13 on specific arginine residues, inhibiting its enzymatic activity; this leads to persistence of VWF-platelet strings in mesenteric venules and accelerates platelet plug formation after vessel injury; elevated ADAMTS13 citrullination was found in sepsis and elderly patients with comorbidities.\",\n      \"method\": \"In vivo r-huPAD4 injection intravital microscopy, mass spectrometry for citrullination sites, in vitro ADAMTS13 activity assays, ferric chloride injury model\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — MS identification of citrullination sites with in vitro functional assay and in vivo validation\",\n      \"pmids\": [\"31248335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"VWF maturation and release are controlled by two distinct regulators of Weibel-Palade body biogenesis: BLOC-2 (required for endosomal input during VWF maturation and WPB exocytosis) and the exocyst complex (which cooperates in WPB formation but clamps WPB release); WPBs from BLOC-2- or exocyst-depleted cells lack high-molecular-weight VWF forms.\",\n      \"method\": \"siRNA depletion of BLOC-2 and exocyst subunits, immunoprecipitation identifying BLOC-2–exocyst interaction, VWF multimer analysis of releasates, Endosidin2 pharmacological inhibition\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal IP, siRNA knockdown with VWF multimer functional readout, pharmacological confirmation\",\n      \"pmids\": [\"32614949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Platelets docking to endothelial VWF during inflammation secrete Angiopoietin-1 (Angpt1) that activates Tie-2 via the Cdc42-GEF FGD5 pathway, preventing vascular leaks during neutrophil extravasation; blocking VWF caused leaks during transmigration.\",\n      \"method\": \"Endothelial Tie-2 gene silencing and knockout, intravital microscopy of cremaster muscle, platelet-derived Angpt1 conditional KO, anti-VWF antibody blocking, fluorescent microsphere leakage assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic KO models with defined molecular pathway and intravital imaging readout\",\n      \"pmids\": [\"32369573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Hyperadhesive VWF released during traumatic brain injury has its A1 domain constitutively exposed; selective blockade with recombinant VWF A2-domain protein reduced TBI-induced death by >50%, prevented TBI-induced platelet activation, microvesiculation, and hypercoagulable state, and protected endothelium from extracellular vesicle injury.\",\n      \"method\": \"Mouse lateral fluid percussion TBI model, A2 domain blockade (IP and IV), platelet activation assays, coagulation assays, mortality and neurological scoring\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conformation-selective blockade in vivo with multiple mechanistic readouts\",\n      \"pmids\": [\"33507292\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Slc44a2/HNA-3a on neutrophils mediates adhesion to VWF at venous shear rates (100 s⁻¹) independently of β2 integrin; HNA-3b expression impairs this adhesion; Slc44a2-KO mice show massively reduced neutrophil recruitment in inflamed mesenteric venules after histamine-induced endothelial degranulation.\",\n      \"method\": \"Flow chamber adhesion assays with transfected HEK cells and donor-typed neutrophils, Slc44a2-KO mouse intravital microscopy\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — allele-specific functional assays in human cells and genetic KO mouse model\",\n      \"pmids\": [\"33556175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"VWF mediates vascular smooth muscle cell (VSMC) proliferation through its A2 domain binding to LRP4 receptor, which signals via αvβ3 integrin; LRP4 and αvβ3 co-localize by proximity ligation and co-immunoprecipitation; VWF-deficient mice show reduced hyperplasia in carotid ligation and femoral denudation models.\",\n      \"method\": \"siRNA against αv integrin and LRP4, RGT-peptide blocking, proximity ligation, co-IP, VWF-KO mouse arterial injury models, confocal microscopy\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple siRNA experiments, co-IP, and in vivo KO with defined pathway\",\n      \"pmids\": [\"33576766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"VWF A1 domain residues K1405–K1408 mediate binding to macrophage LRP1 (clusters II and IV); alanine mutagenesis of this cluster attenuates LRP1 binding and reduces VWF clearance in vivo; the aptamer BT200/rondaptivon pegol prolongs VWF half-life by blocking this interaction and also inhibiting macrophage galactose lectin and SR-AI scavenger receptor binding.\",\n      \"method\": \"LRP1 binding assays, alanine mutagenesis of K1405-K1408, in vivo clearance studies in mice, BT200 competition assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis identifying specific residues in VWF-A1 required for LRP1-mediated clearance, validated in vivo\",\n      \"pmids\": [\"38996211\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Endothelial PTP1B deletion promotes VWF exocytosis by increasing SNAP23 phosphorylation (through reduced PTP1B-mediated tyrosine dephosphorylation of SNAP23), leading to enhanced Weibel-Palade body membrane fusion, neutrophil adhesion, and venous thromboinflammation; NF-κB inhibition restored normal SNAP23 phosphorylation and VWF release.\",\n      \"method\": \"Inducible endothelial PTP1B-KO mice, inferior vena cava ligation, SNAP23 phosphorylation assays, co-IP of PTP1B with SNAP23, anti-VWF antibody blocking, intravital microscopy\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with identified molecular mechanism (PTP1B–SNAP23 axis) and multiple functional readouts in vivo\",\n      \"pmids\": [\"38563147\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"VWF is a large multimeric glycoprotein synthesized as a pre-pro-polypeptide (D1-D2-D'-D3-A1-A2-A3-D4-B-C domains) in endothelial cells and megakaryocytes; the propeptide (D1-D2) acts as an intramolecular chaperone required for disulfide-linked multimerization, after which furin/PACE cleaves the propeptide; mature ultra-large multimers are stored in Weibel-Palade bodies (whose biogenesis requires VWF itself, BLOC-2, and the exocyst complex, with Rab27a/MyRIP anchoring mature WPBs to peripheral actin) and released upon stimulation; shear stress unfolds the A2 domain to enable force-dependent ADAMTS13 cleavage (regulated by chloride-binding to A1 and N-glycosylation at N1574), controlling multimer size; the exposed A1 domain mediates platelet GPIbα catch-slip bond adhesion (regulated allosterically by 14-3-3ζ and by the VWF propeptide binding to D'D3 in plasma), activating downstream signaling through Lyn–cGMP and Lyn/Syk/Btk–TxA2 pathways; the A3 domain binds fibrillar collagen at its hydrophobic front surface; VWF carries and protects factor VIII from proteolysis (FVIII dissociates upon thrombin-mediated activation), and VWF clearance occurs via macrophage/Kupffer cell LRP1 (through A1-domain K1405-K1408) and galactose lectin receptors; VWF also regulates angiogenesis (via Ang-2 and VEGFR-2), VSMC proliferation (via A2-LRP4-αvβ3 signaling), and endothelial barrier integrity during neutrophil extravasation (via platelet Angpt1-Tie-2 axis), with its exocytosis regulated by SNAP23 phosphorylation downstream of PTP1B.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"VWF is a large multimeric glycoprotein synthesized in endothelial cells and megakaryocytes that serves as the principal mediator of platelet adhesion to damaged vessel walls under shear stress and as the protective carrier of coagulation factor VIII in plasma [PMID:3874428, PMID:10881749]. The VWF propeptide (D1–D2 domains) functions as an intramolecular chaperone essential for N-terminal multimerization beyond the dimer stage and for Weibel-Palade body (WPB) biogenesis, with WPB maturation, peripheral anchoring, and regulated exocytosis controlled by Rab27a/MyRIP, BLOC-2/exocyst, and PTP1B–SNAP23 phosphorylation [PMID:3500851, PMID:15331450, PMID:19270261, PMID:32614949, PMID:38563147]. Platelet tethering is mediated by the A1 domain binding GPIbα through a conformationally regulated catch-to-slip bond modulated by A1 disulfide status, dual contact surfaces, and 14-3-3ζ, which triggers intracellular signaling via Lyn→Syk→SLP-76→PI3K→Btk→PLCγ2/PKC/cGMP; the A2 domain contains the ADAMTS13 cleavage site (Tyr1605–Met1606) whose proteolysis is regulated by N-glycosylation at Asn1574, chloride-mediated allosteric stabilization of A1, thrombospondin-1 competition, and PAD4 citrullination of ADAMTS13, while the A3 domain engages fibrillar collagen via a distinct hydrophobic front surface [PMID:14693773, PMID:15941906, PMID:16788103, PMID:20713003, PMID:25293780, PMID:17975018, PMID:16899464, PMID:12447349, PMID:31248335]. Beyond classical hemostasis, VWF tethers to the endothelial surface via A2-domain–vimentin interaction, promotes vascular smooth muscle cell proliferation through A2-domain binding to LRP4/αvβ3, supports neutrophil adhesion via Slc44a2, maintains vascular integrity during inflammation through platelet-derived Angpt1/Tie-2 signaling, and is cleared from plasma through a K1405–K1408 cluster in A1 recognized by macrophage LRP1 [PMID:30355099, PMID:33576766, PMID:33556175, PMID:32369573, PMID:38996211].\",\n  \"teleology\": [\n    {\n      \"year\": 1985,\n      \"claim\": \"Identification of VWF as a single-copy gene on chromosome 12 expressed in endothelial cells established the molecular foundation for understanding its dual roles in platelet adhesion and factor VIII stabilization.\",\n      \"evidence\": \"cDNA cloning, chromosomal localization by in situ hybridization, and Northern blotting\",\n      \"pmids\": [\"3874428\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Megakaryocyte expression not yet formally characterized at this stage\", \"Factor VIII binding site on VWF not mapped\"]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Complete sequencing of the 2813-amino-acid precursor revealed the repetitive domain architecture (D1-D2-D'-D3-A1-A2-A3-D4-B1-B2-C1-C2), providing the structural framework for assigning functions to individual domains.\",\n      \"evidence\": \"Full-length cDNA assembly and in vitro expression in mammalian cells\",\n      \"pmids\": [\"3019665\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functions of individual domains not yet experimentally defined\", \"Multimerization mechanism not resolved\"]\n    },\n    {\n      \"year\": 1987,\n      \"claim\": \"Demonstrating that propeptide deletion blocks multimerization beyond dimers established the D1-D2 propeptide as an intramolecular chaperone required for N-terminal inter-subunit assembly, resolving how high-molecular-weight multimers form.\",\n      \"evidence\": \"Expression of propeptide-deletion VWF cDNA in COS-1 cells with multimer analysis\",\n      \"pmids\": [\"3500851\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise catalytic or structural role of D1 vs D2 not distinguished\", \"Whether propeptide remains associated post-multimerization unclear\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Mutagenesis of Arg611 in the A1 loop showed that this residue is critical for ristocetin- and botrocetin-induced GPIb binding, establishing the A1 domain as the platelet-tethering module.\",\n      \"evidence\": \"Site-directed mutagenesis with transient expression in COS-7 cells and functional binding assays\",\n      \"pmids\": [\"7620154\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic-resolution structure of A1–GPIbα complex not yet available\", \"Shear-dependent bond behavior not characterized\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Biochemical characterization of thrombin-induced FVIII dissociation from VWF clarified how the VWF–FVIII complex serves as a protective carrier and how activation releases FVIII to assemble the factor Xase complex.\",\n      \"evidence\": \"Review synthesizing biochemical activation experiments, phospholipid binding assays, and Xase reconstitution\",\n      \"pmids\": [\"10881749\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Source is a review rather than primary data\", \"Structural basis of D'D3–FVIII interaction not resolved at atomic level\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identification of Ser968 in the A3 domain as essential for collagen binding, combined with NMR mapping of the collagen-binding surface (2003), defined the molecular interface by which VWF anchors to exposed subendothelial matrix.\",\n      \"evidence\": \"Site-directed mutagenesis with collagen binding assays (2001); transferred cross-saturation NMR on A3–fibrillar collagen complex (2003)\",\n      \"pmids\": [\"11583318\", \"12447349\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of A1 and A3 domains to different collagen subtypes under flow not fully delineated\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"A Tyr87Ser mutation in the D1 domain pinpointed D1 as the propeptide subdomain essential for multimerization, refining the intramolecular chaperone model and linking multimerization loss to functional deficiency in collagen and platelet binding.\",\n      \"evidence\": \"Expression of D1-mutant recombinant VWF with multimer and functional binding assays\",\n      \"pmids\": [\"12176890\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether D2 contributes independently to multimerization still open\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Rescue of WPB biogenesis in VWF-null endothelial cells by wild-type VWF demonstrated that VWF itself nucleates Weibel-Palade body formation, establishing VWF as the organelle's structural driver.\",\n      \"evidence\": \"VWF expression in canine VWD aortic endothelial cells with confocal immunofluorescence and P-selectin co-localization\",\n      \"pmids\": [\"15331450\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise tubular packing mechanism of VWF within WPBs not structurally resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Genetic epistasis using knockout platelets defined the GPIb-IX signaling cascade downstream of VWF engagement as Lyn→Syk→SLP-76→PI3K→PLCγ2/PKC, with 14-3-3ζ required for VWF–GPIbα binding, resolving how VWF-mediated platelet tethering converts to intracellular activation.\",\n      \"evidence\": \"Knockout mouse platelets (Lyn, Syk, SLP-76, PLCγ2, LAT, FcRγ) with botrocetin/VWF stimulation; cell-permeable peptide inhibition of 14-3-3ζ–GPIbα interaction\",\n      \"pmids\": [\"15941906\", \"15985541\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How 14-3-3ζ alters GPIbα conformation to enable VWF binding not structurally resolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Btk was placed downstream of PI3K and upstream of PLCγ2/PKC/ERK in the GPIb cascade, and chloride ions were shown to allosterically stabilize A1-A2-A3 to inhibit ADAMTS13 cleavage, revealing two independent regulatory mechanisms — one for signaling and one for proteolytic control of multimer size.\",\n      \"evidence\": \"Btk-KO platelets with in vivo thrombosis model; urea/salt unfolding spectroscopy with ADAMTS13 cleavage assays and type 2B mutant\",\n      \"pmids\": [\"16788103\", \"16899464\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chloride binding site on A1 not mapped at atomic resolution\", \"How physiological ionic strength variation affects cleavage in vivo is unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrating that the N-glycan at Asn1574 sterically shields the ADAMTS13 cleavage site in A2 revealed how post-translational modification gates VWF proteolysis, explaining why unfolding is required to expose the scissile bond.\",\n      \"evidence\": \"PNGase F digestion and N1574A mutagenesis of recombinant VWF with ADAMTS13 cleavage assay and SPR\",\n      \"pmids\": [\"17975018\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether O-glycans also modulate ADAMTS13 cleavage not addressed\", \"Relative contribution under physiological shear not quantified\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Lyn-dependent cGMP elevation was shown to be required for stable platelet adhesion to VWF under shear, adding a cGMP branch to the GPIb signaling pathway independent of TxA2.\",\n      \"evidence\": \"Lyn and Fyn KO platelets with shear flow adhesion, cGMP measurement, and 8-bromo-cGMP rescue\",\n      \"pmids\": [\"18550847\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the guanylyl cyclase activated by Lyn not established\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Rab27a and MyRIP were identified as the machinery anchoring mature WPBs to peripheral actin, linking WPB positioning to the multimerization state and platelet-binding capacity of secreted VWF.\",\n      \"evidence\": \"siRNA depletion in primary endothelial cells with live imaging, flow-based VWF string assay, and multimer analysis\",\n      \"pmids\": [\"19270261\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other Rab27a effectors contribute to WPB anchoring not tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Biophysical analysis showed that A1 disulfide reduction generates a high-affinity intermediate explaining catch-to-slip bond behavior, while TSP1 was identified as a competitive inhibitor of ADAMTS13 at the A2/A3 domains, adding conformational and competitive layers to VWF regulation.\",\n      \"evidence\": \"CD spectroscopy, SPR, and thermodynamic modeling of disulfide-reduced A1 (2010); ELISA and cleavage assays for TSP1 competition (2010)\",\n      \"pmids\": [\"20713003\", \"20705333\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of A1 disulfide reduction not demonstrated\", \"TSP1 competition shown in vitro only (single lab)\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrating that VWF propeptide persists in plasma bound to D'D3 and attenuates platelet adhesion revealed a post-secretion regulatory mechanism for VWF hemostatic function.\",\n      \"evidence\": \"SPR kinetics, anti-D'D3 monoclonal antibodies, flow chamber platelet adhesion, and shear aggregation assays\",\n      \"pmids\": [\"22452980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Proportion of circulating VWF bound by propeptide and its clearance kinetics in vivo not quantified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Knock-in mice carrying A1 mutations at the major (R1326H) and minor (I1309V) GPIbα contact surfaces demonstrated that the kinetic interplay between two binding sites tunes bond lifetime to determine hemostatic outcome, unifying type 2B gain-of-function and loss-of-function phenotypes under one allosteric model.\",\n      \"evidence\": \"VWF-A1 knock-in mice with bond lifetime measurements, bleeding, and thrombosis models\",\n      \"pmids\": [\"25293780\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural transitions at the two-site interface not captured at atomic resolution\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"A synonymous VWF mutation causing pre-mRNA structural rearrangement and intron retention demonstrated that non-coding mutations can cause VWD by disrupting splicing, expanding the mutational spectrum; separately, Vps33b was shown to control VWF trafficking to α-granules in megakaryocytes.\",\n      \"evidence\": \"RT-PCR and confocal imaging of patient blood outgrowth endothelial cells (synonymous mutation); HSC-specific Vps33b KO mice with Co-IP and confocal co-localization (α-granule trafficking)\",\n      \"pmids\": [\"27543438\", \"27319744\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether similar synonymous splicing mutations are common in VWD populations not surveyed\", \"Full complement of Vps33b cargo beyond VWF not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extracellular vimentin was identified as the endothelial anchor for VWF strings via the A2 domain, and blocking this interaction improved cortical reperfusion after ischemic stroke, revealing a therapeutically targetable tethering mechanism.\",\n      \"evidence\": \"Recombinant A2 blocking, anti-vimentin antibodies, vimentin KO mice, and transient MCAO stroke model\",\n      \"pmids\": [\"30355099\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How vimentin is externalized to the endothelial surface mechanistically unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"PAD4-mediated citrullination of ADAMTS13 was shown to inhibit its protease activity and promote VWF-platelet string persistence and thrombosis in vivo, establishing a neutrophil-derived post-translational modification as a regulator of VWF multimer size.\",\n      \"evidence\": \"Mass spectrometry of citrullination sites; ADAMTS13 activity assay; PAD4 injection and Adamts13-KO mice; ferric chloride thrombosis model\",\n      \"pmids\": [\"31248335\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether citrullination operates in chronic inflammatory conditions not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"BLOC-2/exocyst was identified as a WPB maturation and release-clamping complex, and VWF-dependent platelet Angpt1/Tie-2 signaling was shown to maintain vascular integrity during neutrophil diapedesis, expanding VWF's role to vascular barrier regulation.\",\n      \"evidence\": \"siRNA depletion and Co-IP of BLOC-2/exocyst in endothelial cells with WPB morphology and multimer analysis; VWF-blocking antibodies and Tie-2 KO mice with intravital imaging\",\n      \"pmids\": [\"32614949\", \"32369573\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether exocyst directly contacts WPB membrane or acts via BLOC-2 adaptor not resolved\", \"Source of Angpt1 beyond activated platelets not examined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Slc44a2 was identified as a neutrophil receptor for VWF under venous shear, linking a venous thrombosis risk allele (HNA-3b) to impaired neutrophil–VWF adhesion and connecting VWF to venous thromboinflammation; separately, A2-domain blockade of hyperadhesive A1 improved outcomes in traumatic brain injury.\",\n      \"evidence\": \"Flow chamber adhesion with transfected cells and Slc44a2-KO mice with intravital imaging; recombinant A2 domain protein in TBI mouse model\",\n      \"pmids\": [\"33556175\", \"33507292\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise binding site on Slc44a2 for VWF not mapped\", \"Whether A2 blockade is effective in human TBI untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"VWF A2 domain binding to LRP4/αvβ3 was shown to drive VSMC proliferation and arterial hyperplasia, endothelial PTP1B was found to suppress VWF exocytosis via SNAP23 dephosphorylation, and endothelial VWF was demonstrated to be critical for sickle cell vaso-occlusion, broadening VWF's pathophysiological roles beyond hemostasis.\",\n      \"evidence\": \"Co-IP/PLA of LRP4-αvβ3 with VWF-deficient mouse arterial injury models; endothelial PTP1B-KO mice with SNAP23 phosphorylation analysis and IVC ligation; endothelial-specific VWF KO in humanized SCD mice with ADAMTS13 rescue\",\n      \"pmids\": [\"33576766\", \"38563147\", \"35969769\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether LRP4/αvβ3 signaling operates in other vascular beds untested\", \"PTP1B substrate specificity beyond SNAP23 in endothelial exocytosis not defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A K1405–K1408 lysine cluster in the A1 domain was identified as the binding determinant for macrophage LRP1 and other clearance receptors, providing a molecular basis for VWF clearance and validating the aptamer BT200 as a half-life-extending therapeutic.\",\n      \"evidence\": \"Alanine mutagenesis (VWF-4A) with LRP1 binding assays, HEK-LRP1 cell binding, in vivo clearance, and BT200 blocking\",\n      \"pmids\": [\"38996211\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of LRP1, MGL, and SR-AI to total VWF clearance in vivo not quantified\", \"Whether this cluster also affects ADAMTS13 access not examined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the atomic-resolution mechanism by which the D1 propeptide catalyzes disulfide-mediated multimerization, how vimentin is externalized to tether VWF strings, the structural basis of the two-site A1–GPIbα allosteric switch under physiological shear, and the integrated quantitative contribution of glycan shielding, chloride, TSP1, and PAD4 to ADAMTS13 cleavage rates in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No atomic structure of propeptide-mediated multimerization intermediate\", \"No in vivo quantitative model integrating all ADAMTS13 regulatory inputs\", \"Mechanism of vimentin externalization unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 3, 16]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [20]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [4, 14, 18, 24, 26]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [1, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 16, 20, 25]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [7, 13, 22]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [0, 4, 9, 10, 11, 14, 18, 30]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [9, 10, 12, 23, 26]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [24, 27]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2, 3, 11, 31]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [7, 13, 22, 31]}\n    ],\n    \"complexes\": [\n      \"VWF-FVIII complex\"\n    ],\n    \"partners\": [\n      \"ADAMTS13\",\n      \"GP1BA\",\n      \"LRP1\",\n      \"LRP4\",\n      \"SLC44A2\",\n      \"VIM\",\n      \"RAB27A\",\n      \"MYRIP\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"VWF is a large multimeric glycoprotein produced by endothelial cells and megakaryocytes that serves as the primary adhesive bridge between platelets and damaged vessel walls under high shear stress and as the plasma carrier and stabilizer of coagulation factor VIII [PMID:9759493, PMID:10881749]. Synthesized as a pre-pro-polypeptide (D1-D2-D'-D3-A1-A2-A3-D4-B-C domains), VWF requires its propeptide (D1-D2) as an intramolecular chaperone for disulfide-linked multimerization in the ER, after which furin cleaves the propeptide; ultra-large multimers are stored in endothelial Weibel-Palade bodies—organelles whose biogenesis depends on VWF itself and accessory machinery including BLOC-2, the exocyst complex, and Rab27a/MyRIP—and are released upon stimulation to form platelet-catching strings whose size is homeostatically regulated by shear-dependent A2-domain unfolding and ADAMTS13 cleavage, itself modulated by chloride binding, N-glycosylation at N1574, and thrombospondin-1 competition [PMID:3500851, PMID:2251280, PMID:15331450, PMID:32614949, PMID:19498171, PMID:16899464, PMID:17975018]. The A1 domain mediates GPIbα catch-slip bond adhesion—regulated allosterically by propeptide binding to D'D3 and by A1-domain conformational state—activating platelet signaling through Lyn–cGMP and Lyn/Syk/Btk–TxA₂ cascades, while the A3 domain engages fibrillar collagen at its hydrophobic front surface [PMID:8565074, PMID:12183630, PMID:22452980, PMID:15941906, PMID:16788103, PMID:12447349]. Beyond hemostasis, VWF restrains endothelial angiogenesis via VEGFR-2 and Ang-2, promotes vascular smooth muscle cell proliferation through an A2–LRP4–αvβ3 axis, maintains endothelial barrier integrity during neutrophil extravasation via platelet-derived Angpt1–Tie-2 signaling, and is cleared from plasma by macrophage/Kupffer cell LRP1 through A1-domain residues K1405–K1408 [PMID:21048155, PMID:33576766, PMID:32369573, PMID:38996211].\",\n  \"teleology\": [\n    {\n      \"year\": 1985,\n      \"claim\": \"Isolation and chromosomal mapping of VWF cDNA established its identity as an endothelial-cell-derived gene on chromosome 12p, providing the molecular foundation for dissecting VWF structure and disease mutations.\",\n      \"evidence\": \"cDNA library screening from endothelial cells with in situ hybridization mapping\",\n      \"pmids\": [\"3874428\", \"2864688\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter elements and transcriptional regulation not yet defined\", \"Megakaryocyte expression not characterized at this stage\"]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Full-length sequencing revealed VWF's complete domain architecture (D1-D2-D'-D3-A1-A2-A3-D4-B-C), glycosylation map, and dual secretory pathways—constitutive (dimeric) vs. regulated (ultra-large multimers from Weibel-Palade bodies)—establishing the framework for understanding how domain structure relates to hemostatic function.\",\n      \"evidence\": \"Complete cDNA/protein sequencing, in vitro expression in COS-1 cells, immunoelectron microscopy of WPBs, stimulated secretion assays\",\n      \"pmids\": [\"3019665\", \"3524673\", \"3087627\", \"6754744\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of WPB biogenesis unknown\", \"Signals governing regulated exocytosis undefined\"]\n    },\n    {\n      \"year\": 1987,\n      \"claim\": \"The propeptide (D1-D2) was shown to be required for multimerization beyond the dimer stage, functioning as an intramolecular chaperone, while N-glycosylation was found necessary for efficient ER exit—defining two critical quality-control steps in VWF biosynthesis.\",\n      \"evidence\": \"Propeptide-deleted VWF expression in COS-1 cells; tunicamycin treatment and BiP co-immunoprecipitation in CHO cells\",\n      \"pmids\": [\"3500851\", \"3121636\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of propeptide-assisted multimerization unresolved\", \"Disulfide isomerase(s) mediating interchain bonds not identified\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Identification of furin/PACE as the enzyme cleaving the VWF propeptide resolved the maturation step linking pro-VWF to circulating multimers.\",\n      \"evidence\": \"Co-expression of PACE cDNA with VWF precursor in COS-1 cells\",\n      \"pmids\": [\"2251280\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Compartment-specific timing of cleavage relative to multimerization not established\", \"Whether other proprotein convertases contribute in vivo\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Two breakthrough findings—that GPIbα supports fast-on/fast-off platelet tethering under high shear and that VWF undergoes a shear-induced globular-to-extended conformational transition—explained how VWF functions as a mechanosensitive adhesive molecule.\",\n      \"evidence\": \"Flow chamber assays with blocking antibodies; atomic force microscopy under controlled shear\",\n      \"pmids\": [\"8565074\", \"8874190\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of catch bond not yet defined\", \"Which domains unfold first under shear unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Crystal structure of the GPIbα–VWF A1 complex revealed the atomic interface underlying platelet adhesion, while a patient D1-domain mutation (Tyr87Ser) confirmed the propeptide's chaperone role for multimerization and downstream functions.\",\n      \"evidence\": \"X-ray crystallography of GPIbα–A1 complex; patient mutation with recombinant VWF expression and binding assays\",\n      \"pmids\": [\"12183630\", \"12176890\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How flanking domains modulate A1–GPIbα affinity in full-length VWF\", \"Structural mechanism of propeptide-assisted disulfide bonding\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"NMR mapping of the A3 domain–collagen interface to a hydrophobic 'front' surface identified a binding mode distinct from integrin α2-I domains, defining VWF's collagen-recognition mechanism at atomic resolution.\",\n      \"evidence\": \"Transferred cross-saturation NMR on A3–fibrillar collagen complex\",\n      \"pmids\": [\"12447349\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of collagen types I vs III in vivo not resolved\", \"Structural basis of A3–A1 cooperativity unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Reconstitution of WPB biogenesis by re-expression of VWF in VWF-null endothelial cells proved that VWF itself drives WPB formation, recruiting P-selectin and other cargo, establishing VWF as the organizing molecule of its own storage organelle.\",\n      \"evidence\": \"Lentiviral VWF re-expression in canine VWD endothelial cells, confocal immunofluorescence\",\n      \"pmids\": [\"15331450\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Minimal VWF domain requirements for WPB nucleation not defined\", \"Cargo sorting signals for other WPB residents unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Systematic epistasis analysis using knockout mouse platelets placed Lyn, Syk, SLP-76, PI3K, PLCγ2, and Btk in a GPIbα–VWF-triggered signaling cascade leading to TxA₂ production, and identified 14-3-3ζ as an allosteric regulator of GPIb-IX VWF-binding function.\",\n      \"evidence\": \"Multiple KO mouse platelet systems, pharmacological inhibitors, ristocetin agglutination, flow adhesion\",\n      \"pmids\": [\"15985541\", \"15941906\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How GPIbα mechanotransduction initiates Lyn activation at the membrane\", \"Role of LAT and FcRγ in granule secretion vs TxA₂ not fully separated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Discovery that chloride ions bind to the VWF A1 domain and allosterically inhibit ADAMTS13 cleavage of the A2 domain revealed an ionic regulatory mechanism for multimer size control, with disease mutation R1306W reducing chloride affinity.\",\n      \"evidence\": \"ITC, urea-unfolding spectroscopy, ADAMTS13 cleavage assays on isolated domains\",\n      \"pmids\": [\"16899464\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological chloride concentration fluctuations at sites of hemostasis not characterized\", \"Structural basis of allosteric transmission from A1 chloride site to A2 cleavage site\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Site-directed mutagenesis demonstrated that N-glycosylation at N1574 sterically inhibits ADAMTS13 cleavage of VWF, providing a molecular explanation for ABO blood group influence on VWF multimer size and thrombosis risk.\",\n      \"evidence\": \"PNGaseF digestion and N-glycosylation-site mutagenesis in recombinant VWF, ADAMTS13 binding/cleavage assays\",\n      \"pmids\": [\"17975018\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise structural model of how the glycan at N1574 shields the cleavage site\", \"Whether O-glycans also regulate cleavage\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Single-molecule force spectroscopy proved that elongational shear forces unfold the VWF A2 domain in a size-dependent manner (force scales with multimer length squared), with only the unfolded state being an ADAMTS13 substrate—establishing the homeostatic force-cleavage mechanism.\",\n      \"evidence\": \"Optical tweezers on single VWF molecules, ADAMTS13 cleavage of mechanically unfolded A2\",\n      \"pmids\": [\"19498171\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo force measurements at the single-multimer level not achieved\", \"Contribution of A2 refolding kinetics to net cleavage rate\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Rab27a and MyRIP were identified as peripheral actin anchors for WPBs, controlling both distribution and release; their depletion caused premature secretion of less-multimerized VWF, linking WPB positioning to VWF quality.\",\n      \"evidence\": \"siRNA depletion in primary endothelial cells, live imaging, VWF multimer analysis, flow string assays\",\n      \"pmids\": [\"19270261\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Rab27a senses stimulatory signals to release the WPB anchor\", \"Whether MyoVa motor also participates\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"VWF was revealed to regulate endothelial angiogenesis: VWF deficiency causes increased VEGFR-2-dependent proliferation, elevated Ang-2 release, and enhanced vascularization, establishing a non-hemostatic vascular role for VWF.\",\n      \"evidence\": \"siRNA in HUVECs, VWD patient-derived EPCs, in vitro tube formation, VWF-null mouse vascularization models\",\n      \"pmids\": [\"21048155\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which intracellular VWF restrains Ang-2 secretion not fully defined\", \"Whether therapeutic VWF replacement reverses angiogenic phenotype in VWD patients\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Quantitative SPR showed VWF propeptide persists bound to D'D3 in plasma (KD ~25–50 nM), attenuating GPIbα engagement—revealing an unexpected circulating regulatory mechanism for VWF platelet adhesion beyond simple propeptide removal.\",\n      \"evidence\": \"Surface plasmon resonance with anti-D'D3 mAbs, shear-induced platelet aggregation, flow chamber assays\",\n      \"pmids\": [\"22452980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Fraction of circulating VWF bearing propeptide in vivo unknown\", \"Whether propeptide dissociation is shear-dependent\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Knock-in mouse models of A1-domain mutations at two distinct GPIbα contact surfaces demonstrated that the kinetic balance between catch and slip bond regimes dictates the hemostatic-thrombotic boundary, with compensatory double mutations normalizing function.\",\n      \"evidence\": \"VWF-A1 knock-in mice (I1309V, R1326H, double), intravital microscopy, tail bleeding, flow adhesion\",\n      \"pmids\": [\"25293780\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How flanking domains (D'D3, A2) modulate catch-slip kinetics in full-length VWF\", \"Whether therapeutic tuning of bond kinetics is feasible\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"BLOC-2 and the exocyst complex were identified as two independent regulators of WPB biogenesis that together control VWF multimer maturation and exocytosis, closing a major gap in the WPB formation pathway.\",\n      \"evidence\": \"siRNA depletion, reciprocal co-IP of BLOC-2–exocyst, VWF multimer analysis, Endosidin2 pharmacological validation\",\n      \"pmids\": [\"32614949\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BLOC-2 mediates endosomal input into WPBs\", \"Whether exocyst 'clamping' is relieved by specific stimulatory signaling\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"VWF was shown to maintain vascular barrier integrity during inflammation by serving as the platform for platelet docking, which delivers Angpt1 to activate endothelial Tie-2 via Cdc42-GEF FGD5, preventing leaks during neutrophil transmigration.\",\n      \"evidence\": \"Endothelial Tie-2 KO, platelet Angpt1 conditional KO, intravital microscopy, anti-VWF antibody blocking\",\n      \"pmids\": [\"32369573\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this pathway operates in non-inflamed tissues\", \"Relative contributions of endothelial vs platelet Angpt1\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"VWF A2 domain binding to LRP4 receptor, signaling through αvβ3 integrin, was identified as a mechanism by which VWF promotes vascular smooth muscle cell proliferation and intimal hyperplasia, extending VWF's role beyond hemostasis to vascular remodeling.\",\n      \"evidence\": \"siRNA against LRP4 and αv integrin, co-IP, proximity ligation assay, VWF-KO mouse arterial injury models\",\n      \"pmids\": [\"33576766\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether A2 domain must be unfolded for LRP4 engagement\", \"Downstream transcriptional targets in VSMC not identified\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"The VWF clearance mechanism was molecularly defined: A1-domain residues K1405–K1408 mediate binding to macrophage LRP1, and endothelial PTP1B was identified as a negative regulator of WPB exocytosis acting through SNAP23 dephosphorylation—completing both clearance and release arms of VWF homeostasis.\",\n      \"evidence\": \"Alanine mutagenesis of K1405–K1408 with in vivo clearance, BT200 aptamer competition; endothelial PTP1B-KO mice with SNAP23 phosphorylation assays and intravital microscopy\",\n      \"pmids\": [\"38996211\", \"38563147\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of MGL and SR-AI vs LRP1 to total VWF clearance in humans\", \"Whether PTP1B–SNAP23 axis is targetable therapeutically without off-target effects\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis of propeptide-assisted interchain disulfide bonding during multimerization; how VWF intracellularly suppresses Ang-2/VEGFR-2 angiogenic signaling; the in vivo force landscape experienced by individual VWF multimers; and whether the non-hemostatic functions (angiogenesis, VSMC proliferation, barrier maintenance) are therapeutically separable from hemostatic activity.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure of full-length multimeric VWF\", \"Mechanism of intracellular VWF-mediated angiogenesis suppression undefined\", \"Therapeutic strategies separating hemostatic from non-hemostatic VWF functions not developed\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [9, 11, 15, 28, 32]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [9, 11, 42]},\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [12, 17]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [4, 5, 18, 38]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [4, 18, 27, 38, 44]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [10, 26, 36, 40, 41]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [6, 33]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [13, 16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [9, 11, 12, 15, 20, 22, 25, 26, 32, 43]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [4, 18, 27, 38, 44]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [13, 16, 36]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [20, 22, 25, 29, 39, 42]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [5, 6, 8, 24]}\n    ],\n    \"complexes\": [\n      \"VWF–FVIII complex\",\n      \"GPIb-IX-V complex (VWF ligand)\",\n      \"Weibel-Palade body\"\n    ],\n    \"partners\": [\n      \"GP1BA\",\n      \"F8\",\n      \"ADAMTS13\",\n      \"LRP1\",\n      \"LRP4\",\n      \"SNAP23\",\n      \"RAB27A\",\n      \"MYRIP\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}